A RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury

Study Procedures Manual

Intended Audience: Research Coordinators

This study is registered at Clinicaltrials.gov.
Identification number NCT00985205
## Document History

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Superseded Version (Date)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version 1</td>
<td>15 January 2016</td>
<td>Original version</td>
</tr>
<tr>
<td>Version 1.1</td>
<td>09 February 2016</td>
<td>15 January 2016</td>
</tr>
<tr>
<td>Version 1.2</td>
<td>15 March 2016</td>
<td>09 February 2016</td>
</tr>
<tr>
<td>Section</td>
<td>Page</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>Medical Chart Entry</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Electronic Data Capture Systems</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Granting CRS &amp; REDCap™ Access</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Central Randomization System</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Screening &amp; Randomization</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Accessing &amp; Entering a Patient in the CRS</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>Inclusion Criteria</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Exclusion Criteria</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>Pre-Randomization</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>REDCap™ Data Entry</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>Navigating REDCap™</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>My Databases</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Data Entry Field</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Event Grid Field</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>Form Links</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>Form Status</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>Data Conventions in REDCap™</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Investigator Confirmation</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Data Collection Procedures</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Source Documentation</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Study Days</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Patient/Alternate Contact Person(s) Information form</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Baseline form</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Organ Dysfunction form</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>Ventilation/RRT form</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Invasive Mechanical Ventilation</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Renal Replacement Therapy</td>
<td>49</td>
<td></td>
</tr>
<tr>
<td>Burn Grafting Assessment form</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Study Intervention form</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Daily Monitoring of Study IP (Daily Monitoring form)</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>Laboratory form</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Nutrition Assessment/Timing form</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Nutrition Assessment</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Nutrition Timing</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>Daily Nutrition form</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>Burn Related Operative Procedures</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Concomitant Medications</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>Microbiology</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>Protocol Violations</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Hospital Overview</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Month 6 Follow-up Assessments</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>Survival</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>Month 6 Follow-up Assessments: Contact Log</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>Health Related Quality of Life questionnaires</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td>SF-36</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td>Katz ADL Index</td>
<td>67</td>
<td></td>
</tr>
</tbody>
</table>
## Study Contacts

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Contact Details</th>
</tr>
</thead>
</table>
| Dr. Daren Heyland   | Principal Investigator, Coordinating Investigator | dkh2@queensu.ca  
Cell: +1403-915-5573  
Fax: +1613-548-2428 |
| Maureen Dansereau   | Project Leader                            | danserem@kgh.kari.net  
office: +1613-549-6666 ext. 6686  
cell: +1613-888-4320 |
|                     |                                           | **For urgent issues, if unable to reach PL or PI:**  |
|                     |                                           | Janet Overvelde  
CERU Operations Manager  
overvelj@kgh.kari.net  
office: +1613-549-6666 ext. 6241 |
| Chris Gray, CCRP    | Central Pharmacy Manager, Research Pharmacy Consultant | Chris.gray@epipharm.com  
Office: 613-549-6666 ext. 3339 |

All questions related to study procedures should be directed to the Project Leader (PL).

PLEASE NOTE: the Project Leader is blinded. Please take care not to unblind the PL in your communications, written or verbal.

In the event you are unable to reach the Project Leader, please contact the Principal Investigator (PI). If you are unable to reach either the PL or PI, please contact the CERU Operations Manager.

Please direct all questions related to the investigational product, storage, shipping, or resupply to the Central Pharmacy Manager.
Glossary

ACU  Acute Care Unit (ICU or Burn Unit)
ADL  Activities of Daily Living (index of independence)
AE   Adverse Event
APACHE Acute Physiology and Chronic Health Evaluation classification system for severity of disease
CERU Clinical Evaluation Research Unit at Kingston General Hospital (Methods Centre)
CRF/eCRF Case Report Form/electronic Case Report Form
CRS  Central Randomization System
CTN  Clinical Trial Notification (Australia)
CTSI  Clinical Trial Site Information (Canada)
CV   Curriculum Vitae
DAL  Delegation of Authority Log
EDCS  Electronic Data Capture System
EN   Enteral Nutrition
FDA  Food and Drug Administration (USA)
GCP  Good Clinical Practice
HC   Health Canada
hCG  Human Chorionic Gonadotropin (pregnancy indicator)
HOB  Head of Bed
IADL Instrumental Activities of Daily Living (index of functioning)
ICF  Informed Consent Form
ICU  Intensive Care Unit
IP   Investigational Product
IRB  Institutional Review Board
LAR  Legally Acceptable Representative
NA  North America
NOK  Next of Kin
PL  Project Leader or delegate
PN  Parenteral Nutrition
po  orally, by mouth
QIUF Qualified Investigator Undertaking Form (Canada)
RC  Research Coordinator
REB  Research Ethics Board
REBA Research Ethics Board Attestation (Canada)
REDCap™ Research Electronic Data Capture system
SAE  Serious Adverse Event
SD  Study Day
SDM Substitute Decision Maker
SF-36 Short Form 36 (quality of life survey)
SI  Site Investigator
SOFA Sequential Organ Failure Assessment
SSSS Site Staff Signature Sheet
Sub-I Sub-Investigator
TBSA Total Body Surface Area
ULN  Upper Limit of Normal
VS  Vital Signs
Study Synopsis

Overview
The primary purpose of this study is to determine the overall treatment effect and safety of enteral glutamine administration to severely burn injured patients in acute care units (ACUs). We assert that glutamine administration will decrease 6 month mortality, decrease hospital-acquired blood stream infections from Gram negative organisms, reduce acute care unit and hospital length of stay, and improve the physical function of surviving burn injured patients.

Study Design
A large, multicenter, double-blind, pragmatic, randomized controlled trial of 2700 patients with severe burns randomly allocated to receive enteral glutamine or placebo (maltodextrin).

Setting
Approximately 60 tertiary acute care burn centres in Canada, the United States, Australia and Europe.

Study Population
2700 adult patients with deep 2nd and/or 3rd degree burns requiring skin grafting. For patients age 18 – 59 years we require a TBSA (Total Body Surface Area) \( \geq 20\% \), or in the presence of an inhalation injury, a minimum of 15 % TBSA is acceptable. For patients aged 60 years or older we require a TBSA \( \geq 10\% \).

Study Intervention
Patients will receive glutamine or placebo (maltodextrin) through their feeding tube every 4 hours, or orally 3 – 4 times a day, for a total of 0.5 g/kg/day until 7 days after their last grafting operation, or discharge from the acute care unit, or 3 months after admission to the acute care unit, whichever comes first.

Outcomes
Primary outcome: 6-month mortality
Secondary outcome: Time to discharge alive
Tertiary outcomes: Health-related quality of life with particular focus on physical function
Incidence of acquired bacteremia due to Gram negative organisms
Hospital mortality
Duration of mechanical ventilation
Acute care unit length of stay
Hospital length of stay

Trial Duration
Study Recruitment Period
4 years - based on approximately 1 patient per site per month, as demonstrated in the pilot study.

Estimated Total Study Duration
We anticipate the total study duration to be 5 years, broken down as follows: 6 month Start-up period, 4-year recruitment period, and a 6-month follow-up period.
Data processing and Statistical analysis
Data will be collected and managed by the Clinical Evaluation Research Unit, in Kingston, Ontario.

Diagram of Study Overview
Below is a diagrammatic representation of the RE-ENERGIZE Study. Refer to appropriate sections of this Study Procedures Manual for comprehensive instructions for study activities.
Study Preparation

Required Documentation

Prior to site activation (i.e. the initiation of participant recruitment activities) each site must ensure the appropriate regulatory documentation has been completed and is in place. Required regulatory documentation includes, but is not limited to:

- Signed Protocol Signature Page
- Fully-executed Site Agreement
- Ethics Board (REB/IRB) approval
- Ethics approval of Informed Consent Forms (ICFs)
  - Country specific regulatory forms
  - Canada: REBA, CTSI, and QIUF
- Regionally: Local requirements
- CVs & medical licenses for the Site Investigator and sub-Investigators
- Signed Delegation of Authority Log (Appendix A)
- Documentation of study specific training
- Local laboratory reference ranges
- Local laboratory accreditation

Training

Each member of the site research team should be qualified by education, training and experience to assume responsibility for the proper conduct of the trial. The Site Investigator is responsible for ensuring that s/he and the local staff are adequately trained in GCP (GCP 4.1.1) and applicable regulations (e.g. Division 5 training for Canadian sites).

Each Site Investigator and study team member (i.e. Research Coordinator, Dietitian, Pharmacist) must have documented training on the RE-ENERGIZE study prior to initiation of any study procedure, or in the case of new staff joining the study mid-stream, before they initiate any study related duties and/or tasks. Study specific training will be provided by CERU Staff and conducted either in person or via webinar, a corresponding training record will be provided. In instances where members of the research team conducts internal team training related to the study, they should document the training in accordance with their local SOPs (e.g. training record, attendance sheet, etc).

Site Activation

Once the requisite regulatory documents and study specific training has been completed, and clinical supplies are onsite, the CERU PL will request access to the study electronic data capture systems (i.e. CRS and REDCap™) for all appropriate site research staff (e.g. research coordinators and pharmacists). At this point the site is considered activated and may initiate recruitment activities.

Investigator Responsibilities

Per ICH GCP section 4, the Site Investigator is responsible for the conduct of the RE-ENERGIZE STUDY at the participating site. The list below represents an abbreviated version of some of the Site Investigator’s responsibilities (refer to ICH GCP for a comprehensive list of responsibilities):
• Full compliance with the requirements as set out in ICH GCP guidelines
• Protocol compliance
• Ensuring the rights, safety and welfare of the participant is protected
• Acknowledge and retain responsibility for study conduct
  o Personally conduct or supervise the clinical study
  o Ensure that all study staff are informed of their obligations
  o Maintain records of staff qualifications
  o Ensure that mechanisms are in place to ensure that site staff receive the appropriate information throughout the study
  o Ensure that appropriate medical coverage identified for any planned absences (holiday, attending a conference, etc.)
• Confirmation of Participant Eligibility
• SAE Identification and Assessment
  o The site investigator is responsible for identifying, reporting and documenting the onset of serious adverse events (SAEs) during the course of the trial. SAEs should be documented in the subject source documents. It is the responsibility of the investigator to review all documentation (e.g. hospital progress notes, laboratory results, diagnostic reports, etc...) regarding each event.
• Investigator oversight and review of all study specific assessments and investigations.
• Allow monitoring, auditing & regulatory inspections
• Perform Severity of Burn and Grafting Assessments
  o The burn size must be determined by the attending surgeon/physician based on her/his clinical judgment using the Lund and Browder chart (see Appendix B) and documented as percentage of Total Body Surface Area (%TBSA) to confirm eligibility. This assessment must be confirmed by the SI or sub-I.
  o Initial Grafting Assessment
    After written consent has been obtained, the responsible surgeon/physician must assess the deep 2\textsuperscript{nd} and/or 3\textsuperscript{rd} degree burn using the Lund and Browder chart (see Appendix B) to determine the %TBSA expected to require grafting. This assessment must be confirmed by the SI or sub-I.
  o Final Grafting Assessment
    At the end of the study period, defined as 10 days post last successful graft, using the Lund and Browder chart (see Appendix B) the surgeon/physician must assess the %TBSA that actually required grafting. This assessment must be confirmed by the SI or sub-I.

The Site Investigator and any applicable delegates at the research site are also responsible for:
• Supplying a computer and internet access to logon to the CRS and REDCap™
• Maintenance of local computer equipment
• Notifying CERU of any technical difficulties or malfunctions related to the CRS or REDCap™
• Screening & enrolling eligible patients
• Informed Consent of potential research participants/substitute decision makers
• Data collection and entry into the edcs REDCAP™
• Data query resolution

The Clinical Evaluation Research Unit (CERU) will provide training, procedures and tools for study implementation, access to the CRS and REDCap™, and ongoing support of research activities at the site.
Clinical Supplies

Glutamine (Investigational Product)
Glutamine is the ‘active’ arm of treatment for the study.

Glutamine is an amino acid produced normally by the body. It has important functions in regulation of gastrointestinal cell growth, function, and regeneration. Under normal conditions, glutamine concentration is maintained in the body by dietary intake and synthesis from endogenous glutamate. Data from clinical studies indicate that the role of and nutritional requirements for glutamine during burns, catabolic illness, trauma, and infection may differ significantly from the role of and nutritional requirements for glutamine in healthy individuals. Glutamine concentrations decrease and tissue glutamine metabolism increases during many catabolic disease states, and thus burn-injured patients are thought to be ‘deficient’ in glutamine or benefit from supplemental glutamine.

Nutrestore™ (L Glutamine)
Nutrestore™ is an amino acid (L Glutamine) powder that is approved for oral use in short bowel syndrome by the FDA. Refer to product Information sheet (monograph) for more details (Appendix C).

This product is pre-packaged in 5g individual packets.

This will be shipped to you from a central location in North America.

STORAGE: NutreStore™ (L-glutamine powder for oral solution) should be stored at 25°C (77°F) with excursions allowed to 15° - 30°C (59° - 86°F). [See USP Controlled Room Temperature]
**Maltodextrin (placebo)**

Maltodextrin is the ‘control’ arm of the treatment for the study. The ‘control’ has the same visual appearance and taste as the ‘active’ glutamine product used in this study.

Maltodextrins are bland, low sweetness, pharmaceutical grade, white carbohydrate powders that are Generally Recognized As Safe (GRAS) as direct human food ingredients at levels consistent with current good manufacturing practices. They are prepared as a white powder by partial hydrolysis of corn starch with safe and suitable acids and/or enzymes. Maltodextrin is a source of carbohydrate commonly found in standard enteral nutrition and has no metabolic effects other than serving as a source of additional energy. The maltodextrin used in this study contains approximately 19 calories per 5g packet.

**Maltrin® M100 maltodextrin**

The MALTRIN® M100 maltodextrin is produced by Grain Processing Corporation (GPC) and then packaged by Anderson Packaging for the trial. Refer to product Information sheet (monograph) for more details (Appendix D).

This product is pre-packaged in 5g individual packets.

This will be shipped to you from a central location in North America.

**STORAGE:** Store under ambient conditions; protect from excessive heat and excessive humidity for extended periods of time.
Investigational Product Handling and Administration

Duration of study treatment

Patients will receive the study intervention from randomization through 7 days post last successful graft, or ACU discharge, or 3 months from ACU admission, whichever comes first. IP will continue whether the patient is receiving enteral/parenteral nutrition or ventilation status. In the event that the patient is discharged to another facility before the 7 days after the last successful grafting operation, the intervention stops at discharge. Call the Project Leader if you have any questions about the duration of the study intervention.

We recognize that defining the end of study treatment phase by 7 days post last successful graft may not be very exact or precise. There may be unique features to some patients that make it difficult to define. As guidance, we generally mean when the patient is over the acute phase of their illness and either discharged from the acute care unit or entering in their rehabilitation phase.

If the patient requires an additional graft after the IP has been stopped per the duration or treatment defined above, do not restart the IP.

Determination of Dose

Patients will be randomized to receive investigational product (IP), either glutamine or placebo (maltodextrin), at the following dose:

a) Patients with a BMI <35 will receive 0.5 g/kg/day of IP based on pre-burn dry weight (actual or estimated).

b) Patients with a BMI >35 will receive 0.5 g/kg/day of IP based on the adjusted body weight, as per calculation below.

Adjusted Body Weight (ABW) = Ideal Body Weight (IBW) based on a BMI of 25 + [(pre-burn dry weight – IBW) x 0.25]

IP will be dosed in accordance with the patient’s pre-burn dry weight. By dry weight, we mean prior to resuscitation and it is likely consistent with the usual weight recorded on a prior chart or obtained from a family member.

IP Dosing Changes

As detailed above, the study intervention dose calculation is based on the patient’s pre-burn dry weight. All patients will remain on the initially calculated dosage of study intervention for the duration of their participation in the study with one noted exception.

EXCEPTION: If the patient has a change in body weight sufficient for the clinical team to alter dosage of clinical treatments, the study treatment should also be adjusted.

The trigger for the change in IP dose is the change, by the clinical team, in the weight used to dose clinical treatments. Below are examples of events that may trigger a change in IP dose:

- Amputation
- Greater than 10% weight loss.
If there is a change in IP dosing during the study, the following should be documented in REDCap™:

- New dosing weight
- New IP prescription in # grams per day
- Date and Time IP dose changed

Initiation of IP Dosing

The IP (either glutamine or maltodextrin) should be started as soon as possible following randomization but no later than 2h from randomization. Research Coordinator must notify the pharmacy as soon as a patient is randomized to ensure IP is started within the 2h window.

The initiation of study intervention is independent of enteral nutrition, therefore there is no need to wait for enteral nutrition to be started.

Administration

A flow sheet of Nursing Procedures for administration of IP is attached as Appendix E.

Reconstitution of IP

The study intervention will be reconstituted by the nurse or RC at the patient’s bedside just prior to administration.

Each 5 grams of study intervention is to be mixed in 50 mL of sterile or tap water, per your standard procedure, in a clean container.

Administering IP via feeding tube

Once reconstituted, the IP is to be given as a bolus every 4 hours via the enteral route. Boluses are to be given via either a small bore feeding tube or a larger bore gastric/Levine tube. The boluses are to be given via a feeding tube once the latter has been inserted.

**Exception to Dosing Schedule for Patients with a Weight <54kg**

In the event the patient’s pre-burn dry weight is < 54 kg, the interval between some of the doses will be longer (i.e. up to 8 hrs). Refer to Appendix F (Dosing Weight Chart) for more details.

Administering IP when subject no longer needs a feeding tube

When the patient is tolerating oral feeds, the study intervention will be given TID or QID via the oral route according to the patient’s preference, as long as the patient receives the daily prescribed dose in grams.

When the intervention is administered orally, it may be mixed with any non-heated beverage (other than alcohol) or non-heated food such as:

- Yogurt
- Applesauce or Apple Juice
- Cereal
- Potatoes

Avoid mixing the IP with water when administering orally. Patients who participated in the pilot study reported disliking the taste when taking the IP orally when it was mixed with water.
NOTE: There should be no difference in the taste of the glutamine and the maltodextrin.

Mixing the IP with soda or highly acidic juices (such as grapefruit juice, orange juice or lemonade) is not recommended. The IP degrades or becomes unstable in an acidic medium.

**Interrupted or Missed Doses of IP**

While the enteral nutrition may be stopped for procedures and surgeries, you do NOT have to stop the study intervention for procedures or surgery. If possible, the study intervention should be continued as scheduled. In the event that an interruption or a missed dose does happen, the missed doses should be made up the same day by giving additional doses or doubling the scheduled dose, according to the following:

- Doses must be at least one hour apart
- Do not give more than double the scheduled dose at any one time

![Flowchart](chart.png)

**Feeding intolerance and high gastric residual volumes**

High gastric residual volumes are a common occurrence in patients that are receiving enteral nutrition. The administration of the study intervention should continue despite high gastric residual volumes, unless there is an absolute need to stop the intervention i.e. severe vomiting, perforation or leak, bowel obstruction or a decision has been made by the SI/sub-I (i.e. Serious Adverse Event that is felt to be related to the study intervention).

To avoid interruptions in the delivery of the study intervention and enteral nutrition, ensure that strategies such elevating the head of the bed, use of motility agents and small bowel feeding tubes, etc have been adopted. Refer to the Enteral Feeding Protocol (Appendix G) and the Dietitian Manual for more details.

**IP adjustments in subjects with renal dysfunction**

In patients with renal dysfunction, who are not on dialysis, the Glutamine may contribute to elevated urea levels. We are uncertain about the safety of such a high urea level in the absence of dialysis. Some clinicians are comfortable with an isolated high urea; others are not. If the clinical team is uncomfortable with the level of the urea and the patient is not to be dialyzed on the same calendar day, the following guideline is suggested (but not absolutely required):

**Hold Intervention:** Urea/BUN >21.5 mmol/L or >60 mg/dL
At the discretion of the clinical team, study intervention may be restarted when blood urea is below the threshold for stopping. If the patient is on dialysis, regardless of the Urea or Cr levels, the study treatment should not be discontinued or held.

**Study Treatment Allocation**

*Blinding*

All site personnel (i.e. Investigator, sub-ls, coordinators, nurses, dietitians) as well as the central study team are blinded to subject treatment allocations.

*Unblinding*

The investigational products used in the RE-ENERGIZE study are supplements to which there are no antidotes.

In the event of a serious adverse event or medical emergency involving a patient participating in the study, the treatment of the patient is not dependent on the knowledge of the study treatment code. If deemed necessary, the study intervention can be stopped, and no further action is required. If there are questions, contact the Study PI.
Implementation and Recruitment

Patient Eligibility
Screening
Eligible patients may be admitted to either an Intensive Care Unit or a Burn unit. We shall hereafter refer to Acute Care Unit (ACU) to reflect either of these units. Sites should screen subjects admitted to their ACU daily for study eligibility. All of the patients who are screened and meet the Inclusion criteria should be documented using the Central Randomization System (CRS). This information is vital to both the site and CERU to facilitate ongoing discussion regarding recruitment efforts, successes and obstacles. Complete instructions on entry of data into the CRS can be found in the Electronic Data Capture Systems section later in this manual.

Patient eligibility and suitability must be confirmed by the Site Investigator/sub-I. Though any attending physician or surgeon may also be involved in confirming suitability of a patient for the study, it is the site investigator or sub-I that must confirm in writing that the subject is suitable.

Source documentation must be signed, including date and time.

Inclusion Criteria
Patients must meet all inclusion criteria to be eligible for the study.

1) Deep 2nd and/or deep 3rd degree burns requiring grafting
The presence of deep 2nd degree and/or deep 3rd degree burns requiring grafting is an assessment that must be made by the responsible surgeon/physician and confirmed by the SI/sub-I.

<table>
<thead>
<tr>
<th>The following injuries fulfill this criteria</th>
<th>Do NOT include the following burns</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thermal burn injuries:</td>
<td>Do Not include burn injuries from:</td>
</tr>
<tr>
<td>• Scald</td>
<td>• High voltage electrical contact (see exclusion #7.)</td>
</tr>
<tr>
<td>• Fire (includes both Flame and Flash)</td>
<td>• Frostbite</td>
</tr>
<tr>
<td>• Radiation</td>
<td>• Stevens-Johnson Syndrome (SJS)</td>
</tr>
<tr>
<td>• Chemical</td>
<td>• Toxic Epidermal Necrolysis (TEN)</td>
</tr>
<tr>
<td>• Unknown</td>
<td></td>
</tr>
<tr>
<td>• Other, specify__________________________</td>
<td></td>
</tr>
</tbody>
</table>

If you have questions about the acceptability of a particular injury, please contact the PL or PI.

2) Patient meets one of the following 3 criteria:
   a. Patients 18 – 59 years of age with TBSA ≥ 20%
   b. Patients 18 – 59 years of age with TBSA ≥ 15% WITH inhalation injury (see table below for diagnosis of inhalation injury)
   c. Patients ≥ 60 years of age with TBSA ≥ 10%

Diagnosis of inhalation injury requires both of the following 2 criteria:

<table>
<thead>
<tr>
<th>1) History of exposure to products of combustion;</th>
<th>2) Bronchoscopy confirming one of the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>a) carbonaceous material</td>
</tr>
<tr>
<td></td>
<td>b) edema or ulceration</td>
</tr>
</tbody>
</table>

If bronchoscopy is not clinically indicated, it should not be performed for the purposes of the study. The decision to perform a bronchoscopy must be driven by the clinical imperative to diagnosis an inhalation injury.
Exclusion Criteria
A patient is not eligible for the study if any one of the following exclusion criteria is present.

1) **72 hours from admission to Acute Care Unit (ACU) to time of consent**
   This refers to admission to your ACU. If a patient is transferred from another facility, the clock starts from the time of admission to your unit. For patients who are delayed in their presentation and transfer, please do not enroll if the arrival to your ACU is greater than 48 hrs from burn injury.

   The 72 hour window is determined from the time of ACU admission to time informed consent is obtained. While you have 72 hrs to enroll the patients, where possible, we would like to encourage you to enroll and randomize the patient as soon as possible as the beneficial effect of glutamine may be greater if started earlier.

   **NOTE:** Given that consent must occur before randomization, randomization may occur > 72 hours from the time of ACU admission.

2) **Patients younger than 18 years of age**
   There is no upper age limit for patients enrolled in the study.

3) **Patients with renal dysfunction will be excluded. Renal Dysfunction** – defined as:
   In patients **without known renal disease**, renal dysfunction defined as a serum creatinine >171 μmol/L or 1.93 mg/dL or a urine output of less than 500 mL/last 24 hours (or 80 mL/last 4 hours if a 24 hour period of observation is not available).

   In patients **with acute on chronic renal failure** (pre-dialysis), an absolute increase of >80 μmol/L or 0.9 mg/dL from baseline or pre-admission creatinine or a urine output of <500 mL/last 24 hours (or 80 mL/last 4 hours) will be required.

   **Patients with chronic renal failure on dialysis** will be excluded.

4) **Liver cirrhosis Child’s class C liver disease**
   The Child’s class C score is obtained by adding the points for all 5 criteria in the table below.

   Any patient with a score of 10 – 15 falls into Group C (severe hepatic impairment), which would be considered exclusion for this study.

   **Child-Pugh class C scoring table**

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Points assigned</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Bilirubin</strong> SI units</td>
<td>1</td>
</tr>
<tr>
<td>&lt; 2mg/dL or &lt; 34 μmol/L</td>
<td>2 - 3 mg/dL or 34 – 51 μmol/L</td>
</tr>
<tr>
<td>&gt; 3 mg/dL or &gt; 51 μmol/L</td>
<td>&gt; 3 mg/dL or &gt; 51 μmol/L</td>
</tr>
<tr>
<td><strong>Serum Albumin</strong> SI units</td>
<td>2</td>
</tr>
<tr>
<td>&gt; 3.5 g/dL or &gt; 35 g/L</td>
<td>2.8—3.5 g/dL or 28 – 35 g/L</td>
</tr>
<tr>
<td>&lt; 3.5 g/dL or &lt; 35 g/L</td>
<td>&lt; 2.8 g/dL or &lt; 28 g/L</td>
</tr>
<tr>
<td><strong>Prothrombin time or INR</strong></td>
<td>3</td>
</tr>
<tr>
<td>&lt; 4 seconds or &lt; 1.7</td>
<td>4 – 6 seconds or 1.7 – 2.3</td>
</tr>
<tr>
<td>&gt; 4 seconds or &gt; 1.7</td>
<td>&gt; 6 seconds or &gt; 2.3</td>
</tr>
<tr>
<td><strong>Ascites</strong></td>
<td>4</td>
</tr>
<tr>
<td>Absent</td>
<td>Slight</td>
</tr>
<tr>
<td>Slight</td>
<td>Moderate</td>
</tr>
<tr>
<td>Moderate</td>
<td>Severe</td>
</tr>
<tr>
<td><strong>Encephalopathy</strong></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>Moderate</td>
</tr>
<tr>
<td>Moderate</td>
<td>Severe</td>
</tr>
</tbody>
</table>
* Refer to ultrasound results. If ascites has been drained in the past, it should be considered Moderate.

5) Pregnant or lactating females (urine/blood tests for pregnancy will be done on all women of childbearing age by each site as part of standard of ACU practice)

6) Contraindication for EN: intestinal occlusion or perforation, intra-abdominal injury. This refers to an absolute contraindication for EN due to a medical/surgical condition. Being NPO for other reason, such a presumed intolerance to EN, is not considered a contraindication for Enteral Nutrition.

7) Patients with injuries from high voltage electrical contact. There has been extensive discussion by the steering committee regarding the inclusion or exclusion of patients with this type of injury. The determination has been made that burns form high voltage electrical contact are very different from thermal injuries and these patients must be excluded.

8) Patients who are moribund (not expected to survive the next 72 hours in the judgement of the Site Investigator or delegated doctor in charge). Note that an isolated DNR does not fulfil this criteria.

9) Patients with extreme body sizes: BMI < 18 or > 50 kg/m2 When calculating BMI, the patient’s pre-burn dry weight should be used or estimated. Given that there may be some subjectivity involved in the determination of BMI, err on the side of including the patient. For example, if you estimate the weight and the BMI turns out to be 17 or 51, re-set the weight for the patient to be included.

10) Enrollment in another industry sponsored ICU intervention study (Co-enrollment in all non-randomized (observational) academic studies will be approved. For academic randomized controlled trials, forward a synopsis or abstract of the study to the project leader to obtain pre-approval of the study to which you would like to co-enroll. We can not allow co-enrollment in any industry sponsored trials of novel therapeutics or biologics, normally these kind of trials do not permit co-enrollment either).

11) Received glutamine supplement for > 24 hours prior to randomization. This refers to consistent administration of glutamine over the 24 hr period prior to randomization. If the patient received random or intermittent doses of open label glutamine, discontinue the glutamine prior to randomization. If they received glutamine for more than 24 hrs, they will have to be excluded.

12) Known allergy to maltodextrin, corn starch, corn, corn products or glutamine.
**Informed Consent**

“A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject’s decision to participate. Informed consent is documented by means of a written, signed and dated informed consent form.”

-ICH definition of informed consent

The Site Investigator is responsible for consent, even if the tasks associated with obtaining consent are delegated to other study staff.

Following the confirmation of subject eligibility, the site should seek consent. The nature of the RE-ENERGIZE study population is such that subjects are critically ill and often unconscious and in many cases will not be able to grant consent themselves.

Due to the acute care trial setting and the vulnerability of the patient population, informed consent will very often be requested from a third party; in most cases a legally acceptable representative (LAR) or if LAR does not exist, then other, non-legally appointed substitute decision maker (SDM; using a substitute decision maker hierarchy) as defined and permitted by local and state laws and regulations, and if approved by REB/IRB.

Substitute decision-makers are ranked in a hierarchy. The site investigator/research coordinator or delegate is expected to go down the list until a substitute who is available, capable and willing to make the incapable person’s decision is found. The order of hierarchy might differ from region to region, so every site should follow the SDM hierarchy that applies in their own region.

An example of hierarchy is found below:

1) A guardian appointed by the court if the court order authorizes the guardian to make health care decisions
2) A person with a “power of attorney for personal care” authorizing him or her to make health care decisions
3) A representative appointed by the Consent and Capacity Board (any person may apply to the board to be appointed as the substitute decision maker)
4) A spouse or partner
5) A child or parent (custodial parent if the patient is a minor)
6) A brother or sister
7) Any other relative

No study procedure shall begin before written informed consent is obtained.

All subjects must be consented to the study within 72 hours of Acute Care Unit admission. Before you approach for consent:

1) Familiarize yourself with the subject’s history.
2) Approach bedside nursing staff/medical staff for an update on the family’s involvement and their degree of knowledge of the subject’s condition.
3) Confirm subject eligibility and appropriateness of enrollment with the site investigator or sub-investigator.
Recommended Procedures for Obtaining Informed Consent

The following procedures should be followed when obtaining informed consent for a potential RE-ENERGIZE patient:

1) Prior to approaching the SDM to discuss participation in a research study, the attending doctor or delegate should provide an update of the patient’s condition.

2) If the doctor will not be discussing consent with the SDM, a member of the clinical team should introduce to the SDM the research team member who will be discussing consent with the SDM.

3) The study team member obtaining consent is qualified to do so, and is knowledgeable in the study procedures.

4) Review the study details with the SDM in a quiet, private location.

5) Do not coerce or unduly influence the SDM for the patient to participate, or continue to participate in the study.

6) Fully inform the SDM of all pertinent aspects of research, in non-technical language that is easy to understand. If none of the patient’s SDMs speak/read the official language(s) in the study region (e.g. English or French in Canada), consent may be obtained via a translator if this service is available to the research team/hospital. If it is not possible to obtain consent due to “language barriers” this will be noted on the CRS as the reason why the patient’s SDM was not approached for consent.

7) Provide a copy of the consent form to the patient’s SDM and allow for ample time to read it and ask questions.

8) Ask the patient’s SDM questions to assess their comprehension of the material reviewed. Ensure she/he fully understands the information.

9) Ascertain the patient’s SDMs willingness to participate. Document the decision of any patient’s LAR/SDM who declines to participate.

10) Sign and record the date and time written informed consent was obtained:
    a. From the patient’s SDM
    b. By the person conducting the informed consent discussions

11) Document the consent process in the patient’s medical chart.

12) Provide the patient’s SDM with a copy of the signed document.

13) File the originally signed ICF with the study-related documentation. Place a copy in the patient’s medical chart.

Note: The research site should always follow local procedures pertaining to obtaining informed consent of patients in the ACU. If they conflict with what is stated above, follow local procedures.
Procedures for Faxed or Scanned or Emailed or Telephone Consent (where allowed by Ethics Board)

At those clinical sites where local laws and regulations allow and per Ethics Board approval, faxed or scanned or emailed or telephone consent, it is permitted. Ultimately, regardless of the method used to conduct and document the consent discussion, it is necessary to ensure there is written documentation of this process. Every effort should be made to have the consent properly executed in person, with SDM’s original signature obtained, as soon as possible after the fact.

Contact Information

It will be necessary to obtain extensive contact information for the patient, SDM, family and friends to ensure that you are able to reach the patient in 6 months to assess survival and conduct quality of life questionnaires. Refer to Appendix H for a patient/alternate contact person(s) information sheet. Additional information and tips can be found in the Follow-up Procedures document.

Remember to:

- Communicate any important new information that becomes available, and that may be relevant to the subject SDMs continuing consent
- Assess the subject through the duration of the study for competency to grant consent for her/himself
- Document the informed consent process in the source documents, including the following details:
  - SDMs comprehension of the material reviewed
  - SDM being given ample opportunity to review the ICF and decide whether or not to participate in the research
  - Adequate time being given to answer all questions satisfactorily
  - Informed consent having been obtained prior to initiating any study related procedures

Medical Chart Entry

The Research Coordinator will add an entry in the Medical Chart confirming that consent was obtained, from whom, time, eligibility assessed, patient randomized. See Sample entry below.

This patient is enrolled in IRB study ID#, ‘Randomized Trial of Enteral Glutamine to Minimize Thermal Injury’ (The RE-ENERGIZE study). Patient met all the inclusion criteria and none of the exclusion criteria as confirmed with Dr. _________________.

Consent obtained from ________________ (relationship to patient) on dd/mmm/yyyy at time hrs. All questions & concerns addressed with patient/SDM at this time. Copy of consent was given to patient/SDM.

Date/time of entry: _______________________

Signature of Research Coordinator: _________________________

Patient enrolled to the RE-ENERGIZE study at time hrs on date. Patient met all the inclusion criteria and none of the exclusion criteria as
Randomization

Timing of Randomization

All patients should be randomized as soon as possible following receipt of written informed consent. Treatment allocation will be assigned through the Central Randomization System (CRS). Study procedures should be initiated as soon as the patient is randomized. The study intervention should be started within 2 hours after randomization.

Randomizing a patient in the CRS

All patients will be randomized to the study using the CRS. Refer to the Electronic Data Capture Systems in the following section for detailed instructions on navigating the CRS.

Medical/Physician Orders

Following randomization and pharmacy notification, study specific Medical/Physician Orders should be prepared and filed in the medical chart (see example in Appendix I).
Electronic Data Capture Systems

Each site will need to access two different electronic data capture systems for RE-ENERGIZE:

1. **Central Randomization System**
   - The Central Randomization System (CRS) is a web-based system that will be used to screen and randomize eligible patients into the RE-ENERGIZE Study. The CRS may be accessed directly at: [https://ceru.hpcvl.queensu.ca/CRS/](https://ceru.hpcvl.queensu.ca/CRS/) or via: [http://www.criticalcarenutrition.com](http://www.criticalcarenutrition.com)

2. **REDCap™** is a web-based electronic data capture system that will be used as the RE-ENERGIZE Study electronic Case Report Forms (eCRFs). REDCap™ may be accessed directly at: [https://ceru.hpcvl.queensu.ca/EDC/redcap/](https://ceru.hpcvl.queensu.ca/EDC/redcap/) or via: [http://www.criticalcarenutrition.com](http://www.criticalcarenutrition.com)

**Granting CRS & REDCap™ Access**

- Access to both the CRS and REDCAP™ will be granted to the Research Coordinator/delegate upon documentation of training on study procedures and receipt of Ethics Approval documentation and other essential documents.
- Research Coordinators that are granted access to the CRS and REDCAP™ must appear on the Delegation of Authority Log.

**Central Randomization System**

**Screening & Randomization**

All screening data should be entered into the Central Randomization System (CRS).

For eligible patients, the screening data **must** be entered onto the CRS in a timely manner in order to randomize the patient and start the study intervention as soon as possible.

Patient eligibility and suitability must be determined by the Site Investigator or sub-I. Sites are encouraged to use the **Inclusion/Exclusion criteria eCRF worksheets** to document screening and confirmation of eligibility by the SI/sub-I.
Types of Patients to be entered into the CRS

- All patients who meet the inclusion criteria must be entered into the CRS, including:
  - patients that do not meet any exclusion criteria and consent is obtained (Randomized patients)
  - patients that do not meet any exclusion criteria and consent is not obtained (Eligible but Not Randomized patients)
  - patients that meet an exclusion criteria (Not Eligible patients)

The table below provides several examples of the types of patients who should be entered into the CRS.

<table>
<thead>
<tr>
<th>Inclusion Criteria Present</th>
<th>Exclusion Criteria Present</th>
<th>Informed Consent Obtained</th>
<th>Enter into CRS</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓</td>
<td>×</td>
<td>✓</td>
<td>✓</td>
<td>Randomized</td>
</tr>
<tr>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>✓</td>
<td>Eligible but Not Randomized</td>
</tr>
<tr>
<td>✓</td>
<td>✓</td>
<td>Exclusion criteria met - Do not approach for consent</td>
<td>✓</td>
<td>Not Eligible</td>
</tr>
<tr>
<td>×</td>
<td>×</td>
<td>Inclusion criteria Not met - Do not approach for consent</td>
<td>×</td>
<td>Do Not Enter into CRS</td>
</tr>
</tbody>
</table>

Each patient entered into the CRS, will receive a screening number. The screening numbers are assigned sequentially in an 8-character format:

- “Q” indicates the patient is being screened but not randomized
- “R” indicates the patient has been randomized

If the patient is subsequently randomized, they will also be issued a randomization number. The randomization IDs are assigned sequentially in an 8-character format:

- 1002 - Q005
- 1002 - R005

Site #  Patient #
Accessing & Entering a Patient in the CRS

URL: https://ceru.hpcvl.queensu.ca/CRS/

Once you have logged in successfully, you will be brought to the Home screen.

After selecting the “RE-ENERGIZE – Definitive” study from the Home page, you will be brought to the Site Status Page.

To enter a new patient, select the Add patient button on the bottom left of the screen.
Inclusion Criteria

After selecting ‘Add patient’, you will be brought to the Inclusion Criteria form. Complete the fields by clicking on the appropriate radio buttons. Then click ‘Save’.

- Only patients who meet the inclusion criteria should be entered into the Central Randomization System (CRS).
- Eligibility must be confirmed by the Site Investigator/or sub-Investigator before randomization can occur.
Exclusion Criteria

Complete the exclusion criteria fields as appropriate. Choose all exclusion criteria that apply. If a patient meets any of the exclusion criteria, they are not eligible to participate in the study. See the “Exclusion criteria” section for more details.

If a patient is found to meet an exclusion criteria after the patient is randomized, please contact the Project Leader as soon as you become aware for direction on how to proceed.

Pre-Randomization
Pre-Randomization refers to the period of time between the determination of an eligible patient and randomization of a patient. The patient/next of kin must be approached for consent before you complete this form.

Patient Eligibility Confirmed by MD
Confirm eligibility of the patient with the site investigator or sub-investigator. Enter the name of the physician who confirmed patient eligibility. This individual should be listed on the Site Delegation of Authority Log.
Consent
Confirm if the SDM or patient was approached for consent.
• If the SDM/patient was not approached for consent, complete the following form as shown below.

Choose one of the following reasons for NOT approaching for consent:

<table>
<thead>
<tr>
<th>Reason</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Next of kin or substitute decision maker not available</td>
<td>The SDM or legally acceptable representative was not available for consent discussion within the required time frame.</td>
</tr>
<tr>
<td>Missed the patient</td>
<td>The patient was not identified by the site coordinator in time to approach for consent. Example: the patient was admitted over a long weekend.</td>
</tr>
<tr>
<td>Language Barriers</td>
<td>The SDM was not approached because of language barriers. A certified translator was not present.</td>
</tr>
<tr>
<td>Family dynamics</td>
<td>The SDM was not approached due to emotional stress or complicated family dynamics.</td>
</tr>
<tr>
<td>Recommendation of the clinical team</td>
<td>Clinical team does not recommend putting this patient on the study.</td>
</tr>
<tr>
<td>CRS unavailable</td>
<td>The Central Randomization System (CRS) is unavailable.</td>
</tr>
<tr>
<td>Pharmacy unavailable</td>
<td>Pharmacy not available to prepare the investigational product.</td>
</tr>
<tr>
<td>Other (Please specify)</td>
<td>Specify the reason(s) for not obtaining consent that is not listed above. Example: patient received glutamine for &gt;24 hrs before randomization</td>
</tr>
</tbody>
</table>

If the SDM/patient was approached for consent, was consent obtained?
If ‘No’, record the primary reason consent was not obtained:
• Too Overwhelmed
• Not interested
• Did not respond (timed out)
If consent IS obtained, complete all fields on the Pre-Randomization form.

- Other, please specify

Once you click on the “Save” button, the patient will be randomized to the RE-ENERGIZE Study.

**Randomization**

*Randomization must occur soon after consent so that the intervention can start as soon as possible (IP should start within 2 hrs after randomization)*
You may print a copy of the Randomization Form and file in the Patient Folder/Study files. Select 'Print page for your records'.

From the Randomization Confirmation form you can add a new patient, return to the Patient Status Page, or view all patients entered in the CRS by clicking on the corresponding menu option on the left hand side.

The Patient Status Page will show you which forms have been completed for that patient and their status.
Each form has a status assigned:

<table>
<thead>
<tr>
<th>Status</th>
<th>Symbol</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Completed</td>
<td>✔</td>
<td>All data has been completed and saved.</td>
</tr>
<tr>
<td>Not Completed</td>
<td>❌</td>
<td>Data has not yet been entered on the form.</td>
</tr>
<tr>
<td>Locked</td>
<td>🕷️</td>
<td>The patient has been randomized and the form is locked. (Data is no longer able to be edited by the site user.)</td>
</tr>
</tbody>
</table>

If you have made an error and the form is locked please notify the Project Leader to have the data corrected.

"The Patient List allows you to view all patients entered in the CRS and their status. To view a patient, click their Screening ID or their Status.

You will note each patient entered into the CRS is issued a **Screening ID**. Those patients that are randomized are issued a **Randomization ID**.

You will then be brought to the Patient Status screen.

All patient data collected following randomization must be entered on to the eCRF (REDCAP™).
**REDCap™ Data Entry**

The REDCap™ (Research Electronic Data Capture) is a web-based system used for the RE-ENERGIZE Study.

REDCap™ can be accessed at the REDCap™ login link [https://ceru.hpcvl.queensu.ca/EDC/redcap/](https://ceru.hpcvl.queensu.ca/EDC/redcap/).

All authorized study personnel must log onto the web site using their own username and password prior to data entry.

Your user password can be changed at any time by clicking “My Profile” after logging into REDCap™.
Navigating REDCap™

**My Databases**
After you log into REDCap™, you will be brought to the Home screen. Select the “My Databases” tab to see a list of the CERU studies you have access to.

Then select your site number from the dropdown box beside ‘Choose an existing Patient ID’.

**Data Entry Field**
You will be brought to the ‘Data Entry’ page. Once your first patient is randomized, select ‘Arm 2: Laboratory Units’ from the dropdown box on the right following the word ‘from’.

Listed below are the REDCap databases to which you currently have access. Click the database title to open the database. Newly created databases begin in Development status. As you begin to build and design them, when you are ready to begin entering real data in the database, you may move the Production status. To designate the databases as officially collecting data. (When you are finished collecting data or if you wish to step collection, the database may be set to Inactive status, although it may be brought back to Production status at any time when you are ready to begin collecting data again.)

<table>
<thead>
<tr>
<th>Database</th>
<th>Records</th>
<th>Fields</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONTREAT</td>
<td>32</td>
<td>689</td>
</tr>
<tr>
<td>REENERGIZE_I</td>
<td>15</td>
<td>582</td>
</tr>
<tr>
<td>REENERGIZE - Definitive</td>
<td>51</td>
<td>569</td>
</tr>
</tbody>
</table>
Next you will see a grid with only one form, the Laboratory Units form. Click on the green dot to open the form.

The laboratory units form will open.

For each laboratory test listed, select the units the assay is reported in at your site.

This form is only completed once.
The left side of the screen is the main navigation panel. Select ‘Data Entry’ and click in the ‘Choose an existing Patient ID’ box to choose from a list of patients randomized at your site and ready for data entry.

**Event Grid Field**
After you have selected a patient, you will be brought to the Event Grid. The Event Grid gives the user a snapshot of the data entry forms for the patient.

The type of data entry form is listed in the far left column of the table. The study day is listed on the top row of the table. Each dot on the table represents an individual data entry form. Each individual form can be accessed by clicking on the dot. As you can see below, the circled dot is the Daily Monitoring form for study day 3.
Each grid contains 30 study days. The buttons at the top of the grid represent each 30 day segment. To move to a specific set of study days/dates, click the corresponding button or click the ‘Next’ button to navigate to each sequential segment, click the ‘Previous’ button to return to the previous set of study days.

Hospital Overview, Survival Assessment, Contact Attempts Log, and Month 6 Questionnaires all appear after study day 90, on the far right of the 3rd set of study days on the data entry grid.

| Data Entry Form | Day 66 | Day 67 | Day 68 | Day 69 | Day 70 | Day 71 | Day 72 | Day 73 | Day 74 | Day 75 | Day 76 | Day 77 | Day 78 | Day 80 | Day 81 | Day 82 | Day 83 | Day 84 | Day 85 | Day 86 | Day 87 | Day 88 | Day 89 | Day 90 | Outcomes | 6 Month Follow-up |
|----------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Baseline       |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Organ Dysfunction |      |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Ventilation/IVT |      |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Burn Grafting Assessment |   |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Study Intervention     |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Daily Monitoring      |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Laboratory Units       |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Laboratory           |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Nutrition Assessment/Timing        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Daily Nutrition           |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Burn Related Operative Procedures  |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Concomitant Medications |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Microbiology            |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Protocol Violation       |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Hospital Overview        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Hospital Overview        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Survival Assessment       |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Contact Log           |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| SF-36           |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| ADL           |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| IADL           |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| Employment Status       |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |

Slide the navigation scroll bar at the bottom of the table to reveal the right side of the Event Grid.
**Form Links**

You can navigate between forms on the same study day using the form links on the left side navigation menu.

**Form Status**

At the end of each form, you will be asked to specify the form status. This legend is to be used to assist you in remembering what data is incomplete, unverified or complete. The status is indicated on the Event Grid Field using the following convention:

<table>
<thead>
<tr>
<th>Status</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete (red dot)</td>
<td>No data has been entered on a form. Blanks forms will automatically be set to incomplete.</td>
</tr>
<tr>
<td>Unverified (yellow dot)</td>
<td>Data entry is partially completed on a form. The RC wants to double check data already entered on a form. Partially completed forms will automatically be set to unverified.</td>
</tr>
<tr>
<td>Complete (green dot)</td>
<td>Data entry is complete on a form. Further changes to the data are not anticipated. Only forms manually set to complete will have this status.</td>
</tr>
<tr>
<td>Locked (lock symbol)</td>
<td>Locked status will appear on all forms after all finalization checks are completed. Data on locked forms cannot be changed.</td>
</tr>
</tbody>
</table>
**Form Saving**
There may be up to 4 options at the end of each form to save your progress. The following example is for:

**Daily Monitoring - Study Day 1**

<table>
<thead>
<tr>
<th>Option</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Save and go to Day 1 Daily Laboratory</strong></td>
<td>This option will save your progress and bring you to the next form on the same study day. For example, if you are working on the Daily Monitoring form on Day 1, this option will save and bring you to the Daily Laboratory form on Day 1.</td>
</tr>
<tr>
<td><strong>Save and go to Day 2 Daily Monitoring</strong></td>
<td>This option will save your progress and bring you to the same form on the next study day.</td>
</tr>
<tr>
<td><strong>Save and go to Grid</strong></td>
<td>This option will save your progress and return you to the Event Grid.</td>
</tr>
<tr>
<td><strong>Save and Stay</strong></td>
<td>This option will save your progress and allow you to continue working on that form.</td>
</tr>
<tr>
<td><strong>Clear Form</strong></td>
<td>This option will allow you to clear the entire form in case the entire form was completed in error.</td>
</tr>
<tr>
<td><strong>Cancel</strong></td>
<td>This option will take you to the Event Grid screen. All newly entered data will be lost. Only the last saved version will remain</td>
</tr>
</tbody>
</table>

**NOTE:** Always remember to “Save” before you navigate away from a form. Navigating from a form without saving will result in loss of data.

**Data Conventions in REDCap™**

- Dates should be entered using the YYYY-MM-DD format i.e. 2010-07-24. A date picker calendar is available to enter dates. Single “click” on the icon and choose the appropriate month and year from the drop down boxes. Then “click” the appropriate day.

- Enter all times using the HH:MM 24-hour period format i.e. 22:37. The colon ‘:’ must be entered. Use leading zeros where applicable i.e. 01:28.

- Midnight should be entered as 00:00

- To access individual forms single click the corresponding ‘dot’ on the event grid.
- To enter data directly into any text field, **single click** anywhere in the box and type the information.

- Do NOT press enter after entering data into a field. This will cause the form to automatically save and bring you to a new screen that will allow you to return to the Event Grid.

- There should be NO blanks. If data is NOT available use the ‘**Not Available**’ option. This includes:
  - Data that is unavailable because the test was not done.  
    *Example*: *T-Bilirubin was not done on a particular study day.*
  - Data that is not known. This assumes every effort has been made to find the data but it is missing from source documents.
    *Example*: *A particular data point was NOT entered in the medical chart. Or an ICU flow sheet has gone missing.*

- REDCap™ has an option for users to see the data entry history for each data field. By clicking on the **H** just left of the field.

A window will pop up listing the data entry history for that field showing the date and time the data was entered, the user who entered the data, and the data entered at that time.
Stages of Data Entry

To help you determine the status of the patient data, we have designated different stages of data completion. Each stage marks the completion of a specific set of data. The diagram below summarizes the site responsibilities at these various stages.

1) Data Entry Stage
   Enter data on REDCap™ and address blank field and range check

   Once all the data is entered, select "Completed Data Entry" on the patient grid

2) Query Stage
   Address complex data queries

   Once all the queries are answered, the patient will automatically move to the next stage

3) Follow-up Stage
   Complete 6 month Follow-up

   Once all the queries are answered, the patient will automatically move to the next stage

4) Finalized
   Patient chart closed
   Investigator Confirmation Form Completed
Once all data has been completed up to and including hospital overview (Month 6 follow-up excepted), and all simple queries such as missing fields and ranges have been resolved, the user can proceed to the ‘Query Stage’. If all simple queries have been resolved the numbers in the query menu on the left hand side will all be ‘0’. To move to the ‘Query Stage’ click on the ‘Completed Data Entry’ button at the bottom of the Grid.

Once the ‘Completed Data Entry’ button has been selected, REDCap™ will run checks to ensure certain data has been entered. If any data discrepancies are identified the user will see them listed on a new screen.

Each error identified must be addressed before you can move to the “Query Stage”.

There is an individual link to the relevant form to address each error noted.

Once all errors have been addressed the patient will enter the ‘Query Stage’ where complex data queries will fire. Once all queries have been resolved the patient will automatically move to the ‘Follow-up Stage’ and all forms excluding the Month 6 follow-up forms will be locked.

Once a patient is “locked” the site will NOT be able to modify the data.

Contact the Project Leader if modifications to the data are required and we will unlock the form.
After the completion of all data entry (i.e. Status of ‘Finalized’), the Investigator Confirmation form must be completed and forwarded to the Project Leader.

To access the Investigator Confirmation form, select the link from the Resources section on the left side menu.

Investigator Confirmation

The form will automatically be populated with the site name and patient enrollment number. Print this form and have the site Investigator sign and date.

By signing, the site Investigator is attesting to the following:

- The data collection and entry was conducted under his/her supervision and in accordance with study procedures.
- The data and statement, including newly acquired hospital infection adjudication are complete and accurate to the best of his/her knowledge.

Forward a scan of the signed Investigator Confirmation form. File the original in your study files.
**Data Collection Procedures**

The following procedures and associated instructions are also provided in the eCRF worksheets.

All study procedures will be recorded in REDCap™. The following instructions are presented as they appear in the REDCap™ database. Refer to the Electronic Data Capture System section of this Manual for specific instructions related to accessing and using the CRS & REDCap™.

**Source Documentation**

As per ICH GCP (1.51) source documents are original documents, data and records. Site must ensure source documents are available to verify all data collected for the RE-ENERGIZE study.

**Study Days**

Data for the RE-ENERGIZE study is collected and recorded per calendar day from 00:00 to 23:59 daily.

Study Day 1 is defined as **ACU admit date** (not randomization) until 23:59 the same day. Each 24 hour period (00:00 – 23:59) represents a subsequent study day, example below:

Example: A patient is admitted to the ACU on Sept 8th, 2015 at 4:00 PM (16:00). The study days would be:
- Study Day 1 = 2015-09-08 from 16:00 to 2015-09-08 at 23:59
- Study Day 2 = 2015-09-09 from 00:00 to 2015-09-09 at 23:59

**Patient/Alternate Contact Person(s) Information form**

This contact information is obtained to ensure you are able to reach the patient, a family member, friend, or other individual to ascertain survival status and to complete the month 6 follow-up questionnaires. Try to obtain different contacts of the patient and proxies and record it on the patient/alternate contact person(s) information sheet (Appendix H). It is ideal to obtain a alternate contact person(s) that lives with the patient and at least 2 alternate contact person(s) that do not live with the patient. These data are to be collected once, at consent or baseline.

**Baseline form**

These data are to be collected once, at baseline, and recorded in REDCap™.

**Age**

Enter the age of the patient in years at the time of screening (patients must be ≥ 18 years of age to be eligible to participate in The RE-ENERGIZE Study).

**Sex**

Check the appropriate box (male or female).

**Ethnic Group**

Choose the appropriate patient ethnicity from the following list:
- Asian or Pacific Islander
- Black or African American
- East Indian
- Hispanic
- Native
- White or Caucasian
- Other (please specify)

APACHE II
Go to the following website [http://www.sfar.org/scores2/apache22.php](http://www.sfar.org/scores2/apache22.php) to calculate the APACHE II score. Record the calculated score. Reminder: use variables within the first 24 hrs of this ACU admission. If variables are not available from the first 24 hrs, go outside the 24 hr window and use data closest to ACU admission.

NOTE: Ensure the units that you are using for serum sodium, potassium and white blood count are correct.

Comorbidities
Only record comorbidities listed on the Comorbidities list (see Appendix J).

- History of Alcohol abuse
  We would like to monitor the number of subjects that are enrolled in the study who have a history of alcohol abuse. As such, please note that we have added ‘alcohol abuse’ to the Comorbidities list in the CRF under the ‘miscellaneous’ conditions category. Therefore if a subject has a documented history of alcohol abuse in the medical chart, it should be recorded in the CRF.

Tobacco use
Indicate whether the patient is a current smoker or uses tobacco, Yes or No. If you are not able to obtain this information, check the ‘Not Available’ box.

Hospital admit
Enter the date and time of hospitalization. This is the time of initial presentation to your emergency department or hospital ward, whichever is the earliest. If the patient is admitted directly to the ACU, this date and time becomes the Hospital admit date and time. If the admit time is not available, enter the time of the first documentation.

ACU admit
Enter the date and time of ACU admission. If the patient is admitted directly to the ACU, this date and time is the same as the Hospital admit date and time. If the admit time is not available, enter the time of the first documentation.

Is the patient co-enrolled in another academic ACU study?
Indicate if the patient is co-enrolled in another academic ACU study, Yes or No. If Yes, then enter the name(s) of the study(ies).

Burn Injury Date and Time
Enter the date and time the burn injury trauma occurred. If the time of the burn is not available check the ‘No time available’ box.

Type of Burn
Select the type of burn that best describes the nature of the thermal burn injury from the list below (select only one). Frostbite is NOT considered a type of burn for this study.
- Scald
- Fire (Includes both flame and flash burns)
- Chemical
• Radiation
• Unknown
• Other (please specify) ______________

Do NOT Include
• Electrical Burns
• Frost Bite
• Steven-Johnson Syndrome (SJS)
• Toxic Epidermal Necrolysis (TEN)

Burn Size expressed as % TBSA
Record the total burn size expressed as %TBSA as documented by the attending surgeon/physician and confirmed by the SI/sub-I. Record %TBSA in the nearest whole number rounding up from 0.5 and down from 0.4; i.e. if 26.5% is reported, record as 27% and if 26.4% is reported, record as 26%.

Does the patient have an inhalation injury?
Indicate if the patient has an inhalation injury by placing a check in the corresponding box ‘Yes’ or ‘No.’ Smoke inhalation injury is defined as: an injury below the glottis caused by products of combustion. Diagnosis of inhalation injury requires both of the following:
1) History of exposure to products of combustion
2) Bronchoscopy revealing one of the following below the glottis
   • Evidence of carbonaceous material
   • Signs of edema or ulceration

High Dose Vitamin C Resuscitation
Indicate whether the patient received high dose Vitamin C as part of her/his resuscitation protocol, Yes or No.
As a guide, high dose Vitamin C resuscitation is commonly considered approximately 66mg/kg/hr administered for the first 24 - 48 hours after ACU admission.

Organ Dysfunction form
These data are collected once at baseline for calculation of modified SOFA.

Vasopressors
Indicate whether or not the patient received vasopressors.
If ‘Yes’, select the highest dose received from the 3 groupings below:

- Dopamine ≤ 5 µg/kg/min or Dobutamine (any dose)
- Dopamine 6 - 15 µg/kg/min or Epinephrine ≤ 0.1 µg/kg/min or Norepinephrine ≤ 0.1 µg/kg/min
- Dopamine > 15 µg/kg/min or Epinephrine > 0.1 µg/kg/min or Norepinephrine > 0.1 µg/kg/min

If ‘No’, enter MAP (mean-arterial pressure), see below.
MAP (lowest)
Indicate the lowest MAP observed during the study day by selecting one of the options below:

- < 70 mmHg
- ≥ 70 mmHg

If the MAP is not available you can calculate it using the formula:

\[ MAP = \frac{1}{3} \text{ lowest systolic BP} + \frac{2}{3} \text{ corresponding diastolic BP} \]

Example: Lowest systolic B/P was 140/90
1/3 Systolic: 46.7
2/3 Diastolic: 60
MAP: 46.7 + 60 = 106.7

Or use the tool on the website: http://www.mdcalc.com/mean-arterial-pressure-map/

Urine output (mL)
Place a check in the appropriate volume range for urine output for the study day.

- < 200 mL/day
- < 500 mL/day
- >= 500 mL/day
- Not Available

Ventilation/RRT form

Invasive Mechanical Ventilation
Duration of Data Collection
These data are to be collected at start and stop of invasive mechanical.

If the patient receives invasive mechanical ventilation during the study, record the associated start and stop dates/times in REDCap™.

Did the patient ever receive invasive mechanical ventilation?
Indicate if the patient ever received invasive mechanical ventilation, Yes or No.

Ventilation Event 1
Invasive Mechanical Ventilation #1 Start
If the patient received invasive mechanical ventilation, place a check in the Yes box and record the actual start date and time of invasive mechanical ventilation, even if this occurs at an external institution or in the field before admission to your unit. This may not be the same time that the patient was intubated, but should be the time invasive mechanical ventilation was started.

Do not record episodes of temporary ventilation (defined as <48 hrs i.e. needed for operating procedures, etc).

Invasive Mechanical Ventilation #1 Stop
Record the date and time the invasive mechanical ventilation episode was discontinued.
For patients that are on and off the ventilator, the patient is considered to be ventilator free if they are successfully breathing without mechanical ventilation for > 48 hours. In this event, record the date and time the ventilation was actually discontinued (i.e. in this instance, the start of the 48 hrs).

Patients will be considered breathing without mechanical ventilation in any of these instances:
- extubated and on face mask (nasal prong)
- intubated or breathing through a t-tube
- tracheostomy mask breathing.
- continuous positive airway pressure (CPAP) <=5cmH2O without pressure support or intermittent mandatory ventilation assistance.

If patient is transferred out of the ACU to another institution and is still receiving mechanical ventilation, record the transfer date and time as the mechanical ventilation discontinuation date and time.
If the patient expired while mechanically ventilated, check the box titled ‘Same as death date & time’.
If the patient is still mechanically ventilated 3 months after ACU admission, check the box titled ‘Still vented at Day 90’.

**Ventilation Event 2**
**Invasive Mechanical Ventilation #2 Start**
In the event that the patient is restarted on invasive mechanical ventilation after being extubated successfully for 48 hrs, place a check in the Yes box. Do not record episodes of temporary ventilation (defined as <48 hrs).

Record the date and time invasive mechanical ventilation was restarted.

If patient never restarted invasive mechanical ventilation, then check the box titled ‘Did not restart invasive mechanical ventilation’ and proceed to the dialysis section

**Invasive Mechanical Ventilation #2 Stop**
Record the date and time the invasive mechanical ventilation episode was discontinued.

**Ventilation Event 3, 4, 5**
**Invasive Mechanical Ventilation #3, 4, 5**
Follow the instructions as listed for Mechanical Ventilation start # 2 and stop # 2 for the third, fourth, and fifth episodes of mechanical ventilation, if applicable.

**Renal Replacement Therapy**
**Duration of Data Collection**
These data are to be collected at start and stop of renal replacement therapy (dialysis).

If the patient receives renal replacement therapy during the study, record the associated stop and start dates/times in REDCap™.

**Did the patient receive renal replacement therapy (dialysis) during this ACU stay?**
Indicate if the patient received renal replacement therapy (dialysis) during this ACU stay.
The first time renal replacement therapy (dialysis) was started, was it due to acute renal failure? Indicate if the first time renal replacement therapy (dialysis) was started was due to acute renal failure. If Yes, continue to the next question. If No, the dialysis section is complete.

Renal Replacement Therapy (Dialysis) Stop
Record the start date of RRT.

RRT stop date
Record one of the following:

- Same as death date & time
- At 3 months, still on renal replacement therapy (dialysis) in hospital
- Continued past hospital discharge
- Actual stop date →

If selecting ‘Actual stop date’, record the date RRT was permanently discontinued.

**Burn Grafting Assessment form**
These data are collected twice for each patient, once at the beginning of the study and once at the end of the study period.

*Initial Grafting Assessment*

Date of initial assessment
Record the date the initial assessment was completed by the attending surgeon/delegate.

If the Grafting Assessment was completed when determining eligibility, record the date of that assessment.

Deep partial/full thickness burn (expected to require grafting) %
The responsible surgeon/physician must assess the deep 2nd and/or 3rd degree burn using the Lund and Browder chart (see Appendix B) to determine the percent Total Body Surface Area (%TBSA) expected to require grafting. This assessment must be confirmed by the SI or sub-I. Record the %TBSA expected to require grafting.

- Reminder: Deep 2nd and/or 3rd degree burn requiring grafting is an inclusion criteria. This should not be zero.

**Last Successful Graft**
Indicate whether or not the last successful grafting was achieved

If ‘Yes’, enter the date in the format yyyy-mm-dd.

If the last successful graft was never achieved, select the reason:

- Death
- Withdrew Consent (including consent for data collection)
- Withdrew Life Sustaining Therapies
- Discharged without receiving a graft
- Receiving grafts after ACU discharge (< 3 mo.)
Still receiving grafts in ACU at 3 months
☐ Other, specify: ___________________________________

If ‘death’ or ‘withdrew consent’ is indicated, do not record the Final Assessment.

Final/Last Grafting Assessment
A Final/Last Burn assessment must be completed on all patients, even if they are still receiving grafts or expected to receive additional grafts at the time of the assessment.

Exception: Do not record final assessment if ‘Death’ or ‘Withdrew Consent’ was indicated in the ‘Last Successful Graft’ section above.

Date of final/last assessment
Record the date the final/last assessment was completed by the attending surgeon/physician. The assessment must be done at the end of the study duration, defined as 10 days post last successful grafting, or ACU discharge, or 3 months from ACU admission, whichever occurs first.

Area that required grafting
At the end of the study period, using the Lund and Browder chart, the surgeon/physician must assess the %TBSA that required grafting. This assessment must be confirmed by the SI/sub-I.

Record the actual, or total at the time of assessment, %TBSA that required grafting as determined by the surgeon/physician on the date of the final/last assessment. This may be more, less or equal to the initial area expected to require grafting.

The Final Assessment should be recorded as %TBSA, not a percentage of the Initial Assessment expected to require grafting.

Example: Initial Grafting Assessment expected to require grafting = 25% TBSA
Final Grafting Assessment - area that actually required grafting = 25% TBSA

Final Grafting Assessment is recorded as 25% TBSA.
In the example above, do not record the final assessment as 100% TBSA

Study Intervention form
Study intervention is to be started within 2 hours of randomization.

Duration of Data Collection
These data are to be collected when study supplements are first started and when study supplements are finally stopped.

In addition, any prescription changes will be recorded on the Study Intervention form.

Study Intervention

Date and time the first dose of study intervention was administered
Enter the date and time study supplements were first started in the format yyyy-mm-dd and hh:mm

Was Study Intervention started > 2 hours after Randomization?
If study intervention was started, indicate ‘Yes’ or ‘No’ by placing a check in the corresponding box.

If the study intervention is started more than 2 hrs after randomization, select ‘Yes’ and choose the reason from the list provided (below):

- Pharmacy delay
- Patient NPO for surgery
- Awaiting tube placement and/or verification
- Patient not available (procedure)
- Nurse not available
- Other (specify): ____________________________

If you select ‘Other’, you must provide an explanation in the space provided.

Date and time the last dose of study intervention was administered
Enter the date and time study supplements were finally stopped in the format yyyy-mm-dd and hh:mm

The stop date should be at the end of the study period i.e. 7 days after the last successful grafting operation or at discharge from ACU or 3 months from ACU admission, whichever occurs first.

**Study Intervention Prescription**
What was the study intervention prescription?
Record the initial study intervention prescription in grams/day.

Each packet contains 5 grams of study intervention. If 10 packets per day are to be given, enter 50 in the prescription box.

Did the study intervention prescription change?
If the study intervention prescription changes, record the new prescription and date/time the change occurred.

NOTE: IP prescription should not change.

Exception: if the patient has a change in body weight sufficient for the clinical team to alter dosage of clinical treatments (such as an amputation), the study treatment should also be adjusted.

**Daily Monitoring of Study IP (Daily Monitoring form)**

These data are collected to determine the compliance to the prescribed dose of the study intervention and to identify any dose related Protocol Violations.

Study intervention is to be started within 2 hours of randomization.

**Duration of Data Collection**
Given the material effect on the study, these data are to be collected daily as close to REAL TIME as possible and as follows:
• Study Intervention: from randomization to 7 days post last successful grafting operation, or until ACU discharge, or until 3 months from ACU admission, whichever comes first.
• Dose related Protocol Violations: for duration of study intervention administration.

NOTE: Duration of Study Intervention is from randomization to 7 days post last successful graft, or until ACU discharge, or until 3 months from ACU admission, whichever comes first.

**Prescribed # grams per day**
At the top of each page record the number of grams per day of investigational product (IP) the patient is to receive.

NOTE: This is to assist you in determining the daily percentage of IP received. This data is not collected on the Daily Monitoring form in record.

**Date**
Enter the date corresponding to the calendar day for the data being collected. Select the study day in REDCap™ on which the recorded date appears to enter the data associated with this date.

**# Times the IP was given**
Select the number of times, (0 to 10) from the dropdown list the, the study intervention was given on each study day.

**# Grams given**
Select the # grams given, (5 to 30) from the drop down list, at each interval as documented in the medical chart.

Each packet of study intervention contains 5 grams.

If dose is recorded in the medical chart as # of packets administered, multiply # of packets by 5 and select the # of grams administered.

**Route**
Select the route by which the study intervention was administered at each interval:
• PO
• EN

**Percentage of study intervention received**
Divide the total number of grams actually given on each study day by the number of grams prescribed per day (documented at the top of the page) to determine the percentage of study intervention received. Record the percentage in the space provided.

**Was there a dose related Protocol Violation today? (IP dosing <80% over a 3 day average)**
A protocol violation with the delivery of the study intervention occurs when the patient receives < 80% of the total prescribed daily dosage over a 3 day average.

Report a dose related protocol violation when both of the following are true:
• Dose received on the indicated day is < 80% prescribed
• Dose received over a 3 day average is < 80% prescribed

In the event that the patient does not receive at least 80% prescribed daily dosage over a 3 day average, a Protocol Violation Form must be completed in REDCap™ within 24 hours of becoming aware. Refer to the Protocol Violation instructions later in this section.

**Laboratory form**

If blood chemistry and/or hematology testing are conducted per standard of care, enter the indicated results in REDCap™ according to the following schedule:

**Duration of Data Collection**
These data are to be collected as follows:

- **Daily for 2 weeks:** From admission to the ACU through study day 14
- **Weekly:** From day 15 to 10 days post last successful graft, d/c from the ACU, or 3 mos. after admission, whichever comes first.
  - Collect weekly lab data from a single day during that study week defined as +/- 24 hours from study day 21, 28, 35, 42, 49, 56, 63, 70, 77, 84 and 90.
  - If there is no value available on the specified date, record the value from an adjacent day. If there is no value available for that study week, record N/A.

**Laboratory Values**
Record the highest or lowest for the day as indicated below. Exception: record glucose taken closest to 8:00 AM:

- Creatinine (highest)
- Bilirubin, total (highest)
- Urea (highest)
- PaO2/FiO2 (lowest)
- Glucose (8:00 AM)
- Ammonia (highest)
- Albumin (highest)
- Lactate (highest)
- Platelets (lowest)
- WBC (highest)
- WBC (lowest)

  - The PaO₂ and FiO₂ values should come from the same blood gas measurement.
  - If there is only one WBC value recorded for the 24 hr period, record the one value as both the highest and lowest.

If a laboratory value is not available, select ‘Not Available’.

**Nutrition Assessment/Timing form**
In the following section, the word dietitian refers to the team member responsible for assessing and monitoring the patients’ nutritional needs during the course of the study.

**Nutrition Assessment**
These data are collected to determine how well the patient is being fed, e.g. the nutritional adequacy (% calories and protein received/prescribed). Refer to the Dietitian Manual for detailed instructions for the nutrition assessment.
Duration of Data Collection
The nutrition prescription for calories and protein will need to be calculated by the dietitian at baseline (ACU admission or at the first dietitian assessment) and as needed thereafter.

Baseline Assessment
Record the date the baseline prescription was calculated. Record the total calories prescribed (kcal) and the total protein prescribed (grams).

If the prescription changes for this patient, enter the date, total calories prescribed (kcal) and the total protein prescribed (grams) of the new prescription.

Prescribed Energy and Protein needs
Contact your dietitian to obtain this information. These will need to be calculated by the dietitian at baseline (ACU admission or at the first dietitian assessment) and thereafter.

The dietitian is to use the patient’s pre-burn dry weight when calculating the nutrition prescription. For obese patients, if your standard practice is to adjust for obesity, follow your standard practice. If you do not have an obesity adjustment practice, use the formula below:

\[
\text{Adjusted Body Weight (ABW)} = \text{Ideal Body Weight (IBW)} \text{ based on a BMI of 25} + [(\text{pre-burn dry weight} - \text{IBW}) \times 0.25]
\]

Prescribed energy needs are to be calculated using Indirect Calorimetry, a predictive equation, or a simple weight-based formula but on average, should not lead to a prescription of less than 30 kcal/kg.

Prescribed Protein needs are to be calculated using the following:
- If > 50% burns, use 1.5g/kg/day to 2.5g/kg/day
- If < 50% burns, use 1.2 g/kg/day to 2g/kg/day

Prescription changes
If the prescription changes from baseline during the study, indicate ‘Yes’ to the question ‘Was another prescription made?’ and record the date, total calories prescribed (kcal), and total protein prescribed (grams) in the corresponding rows. Up to 6 prescriptions may be entered for each patient.

Note: Energy and protein requirements are independent of the enteral formula prescribed. Do NOT change prescription to accommodate an enteral formula change.

Nutrition Timing
These data are collected to determine the timing of initiation of nutrition.

Enteral Nutrition
Was EN received during this ACU admission?
Indicate if the patient received EN during this ACU admission or not, Yes or No.

Date/Time
If the patient received EN, record the following:
- the start date and time of EN.
• the stop date and time of EN. This refers to the date EN was permanently discontinued, not stopped for temporary interruptions.

If EN is continued beyond ACU discharge, record ACU discharge date and time as the date and time that EN was stopped. If the patient is still receiving EN in the ACU at 3 months, place a check in the box titled ‘Still on EN at 3 months in ACU’.

**Parenteral Nutrition**

Was PN received during this ACU admission?
Indicate if the patient received PN during this ACU admission or not, Yes or No.

**Date/Time**
If the patient received PN, record the following:
• the start date and time of PN.
• the stop date and time of PN. This refers to the date PN was permanently discontinued, not stopped for temporary interruptions.

If PN is continued beyond ACU discharge, record ACU discharge date and time as the date and time that PN was stopped. If the patient is still receiving PN in the ACU at 3 months, place a check in the box titled ‘Still on PN at 3 months in ACU’.

**Daily Nutrition form**
The number of calories and protein received by the patient, the route by which they were administered, and the source will be recorded daily and entered into REDCap™. These data should be obtained from the Dietitian.

**Duration of Data Collection**
These data are to be collected daily from Study Day 1 (ACU admission) until 10 days post last successful grafting or ACU discharge or 3 months from ACU admission, whichever comes first.

This data is to be collected daily whether the patient is receiving enteral nutrition, parenteral nutrition or neither.

**Enteral Nutrition**

Was Enteral Nutrition (EN) given?
For each day, indicate whether the patient received EN, Yes or No.

If ‘No’ to EN, using the list below, indicate ALL the reason(s) the patient did not receive EN on the specified Study Day by placing a check in the box(es) provided:

- NPO for endotracheal extubation or intubation or other bedside procedure. If ‘Other’ is indicated, please also check the ‘Other’ box and specify the reason.
- NPO for operating procedure
- NPO for radiology procedure
- High NG drainage
- Increased abdominal girth, abdominal distension or pt. discomfort
- Vomiting or emesis
- Diarrhea
- No enteral access available / enteral access lost, displaced or malfunctioning
- Inotropes, vasopressor requirement
- Patient deemed too sick for enteral feeding
- On oral feeds
- Reason not known
- Other, please specify ________________

EN Formula
If ‘Yes’ to EN, using the EN Formula List (Appendix K), choose the number that corresponds to
the type of enteral formula received. You may record up to 3 different formulas used in a day.
Record the first formula received in the spaces provided for ‘Formula 1’ and so on. If the formula
given is not in the EN Formula List, select #82. Other Nutritional Formula and enter the name of
the formula in the space provided. In the event that the patient receives more than 3 formulas in
one day, select the 3 formulas that provide the largest volumes.

Total kilocalorie and protein received from EN
Record the total calories (kilocalories) and protein from all of the enteral nutrition formulas
received in the study day.
- Do not include the calories from IV solutions, e.g. Dextrose (collected separately).
- Do not record the calories from Propofol (volume entered separately).
- Do not include protein supplements as part of this total (collected separately).

Protein Supplements
Was a protein supplement given?
Record whether a protein supplement was received, ‘Yes’ or ‘No’.

Protein supplement name
If protein supplement was received, record the number or name from the Protein Supplement
List (Appendix L).

Add another protein supplement?
If there is more than one protein supplement, record the name of each supplement by ticking
‘Yes’.

Total kilocalorie and protein received from protein supplements
Record the total calories and protein received from protein supplements.

Parenteral Nutrition
Was Parenteral Nutrition (PN) given?
For each day, indicate whether the patient received PN, Yes or No.

Total kilocalories and protein received from PN
If yes, record the total calories (kilocalories) and grams of protein received from PN for that
study day.
- Do not include the calories from IV solutions, e.g. Dextrose (collected separately).
- Do not record the calories from Propofol (volume entered separately).

IV Fluids containing Glucose
Was IV fluid containing glucose given?
Indicate whether the patient received IV fluids containing glucose that day, ‘Yes’ or ‘No’.
Total kilocalories received from IV fluids
If yes, record the total calories (kilocalories) received from IV fluids containing glucose for that study day.

If the kcals from IV fluids are not provided to you by the dietitian, you can calculate the kcals as follows:

1. Determine the dextrose (glucose) concentration of the IV fluid received:
   a. D5W = 5% dextrose
   b. D10 = 10% dextrose

2. Determine the volume (mL) the patient received, as documented in the chart.

3. Calculate the amount of glucose received in grams by multiplying the concentration of the solution by the volume received:
   \[
   \text{Concentration (\%)} \times \text{Volume (mL)} = \text{Grams received}
   \]
   Example: Concentration: D5W = 5%        0.05
   Volume recorded: 1200 mL    X 1200
   Grams glucose received:    60g

4. Calculate the calories from the glucose received in the IV fluid by multiplying the grams received by the kcal/g contained in the dextrose solution:
   a. Dextrose solutions contain 3.4 kcal/g
   Example: 60g   X   3.4 kcal   =    204 kcal

In this example above, the patient that received 1,200 mL of D5W received 204 calories (kcals) from IV fluid containing glucose.

Oral Nutrition
Was Oral Nutrition given?
Indicate whether the patient received any oral intake today, Yes or No

Propofol
Was Propofol received for \( \geq 6 \) hours?
Indicate whether the patient received a continuous infusion of Propofol for \( \geq 6 \) hrs, Yes or No.

Total volume of Propofol received
If yes, record the total volume in mL of Propofol received that day.

Burn Related Operative Procedures
All burn related operative procedures, type of procedure, and whether it was planned or unplanned will be recorded in REDCap™. Record the procedure in REDCap™ on the date the procedure occurred.

Duration of Data Collection
This data should be collected from admission to the ACU until 10 Days post last successful grafting operation, or discharge from the ACU, or 3 months after admission to the ACU, whichever comes first.
Note: This data only needs to be collected on days a burn related operative procedure is performed.

Burn related operative procedure today?
Indicate if there was a burn related operative procedure today by selecting ‘Yes’.

Was the Operative procedure planned or unplanned?
Indicate if the operative procedure was planned or unplanned.

Type of operative procedure
Select the type(s) of operative procedure(s) performed on each study day from the taxonomy provided, see below. Select all that apply.
- Surgical excision (tangential or fascial)
- Excision and temporary covering (xenograft, allograft and artificial skin)
- Excision and autograft
- Delayed autograft
- Excision and primary closure/composite tissue transfer
- Other specify—example amputation

If you select ‘Other’, you must specify the procedure in the space provided.

Concomitant Medications
Record only the 5 concomitant medications or medication types indicated below.

Duration of Data Collection
Administration of the following concomitant medications will be recorded in REDCap™ from admission to the ACU until 10 Days after the last grafting operation, or discharge from the ACU, or 3 months after admission to the ACU, whichever comes first:

Were concomitant medications received today?
Indicate if concomitant medications were received today, Yes, No or Not Available.

Concomitant Medications
Indicate ‘yes’ or ‘no’ regarding administration of each of the following medications. If the information is not available, indicate by selecting the corresponding box:
- **Insulin**
  If insulin was given, record the total units received in the 24 hour period from all insulin IV, SC (subcutaneous) and bolus.
- **Opiates**
- **Motility agents** (metoclopramide, erythromycin, domperidone, other)
  Do NOT record stool softeners here.
- **Oxandrolone**
- **Propanolol**

Microbiology
Record only the following microbiology data in REDCap™.
Only record venous or arterial blood cultures that test positive for **Gram negative bacteria** that occurred >72 hours after ACU admission until 10 days post last successful grafting or ACU
discharge or 3 months from ACU admission, whichever comes first. Do not include blood from a catheter line tip.

**Date**
Complete the date the sample was collected (i.e. not when the results were reported) in the date format of yyyy-mm-dd.

**Time**
Complete the time the sample was collected (i.e. not when the results were reported) in the format of hh:mm.

**Multiple samples on the same day**
If multiple cultures are taken on the same study day, record all different Gram negative bacteremia reported. Do not record the same bacteria more than once on each study day, even if reported from specimen collected at different times on that day.

**Gram Negative Culture #**
Record the name, or the corresponding number on the taxonomy, of the Gram negative bacteria reported, refer to Appendix M for a list of Gram negative bacteria to be recorded and Gram positive bacteria that are not be recorded. If there is a Gram negative bacteria reported that does not appear on the list, select #44 Other and specify the bacteria name in the space provided.

**Protocol Violations**
A Protocol Violation is defined as non-compliance with the study protocol and/or procedures that may impact study participant safety, the integrity of study data and/or study participant willingness to participate in the study.

Compliance with the study procedures will be monitored by the central study team. Any deviation or failure to conduct procedures and assessments required in the protocol should be documented and reported to the central study team via REDCap™ by completing the Protocol Violation form within 24h of becoming aware of the violation. You do not need to print and fax the form to the project leader. An automated email notification will be generated and sent to the project leader within 24 hours of the data being entered into REDCap™.

Each site is responsible for determining if and when a protocol violation should be reported to the local REB.

Some examples of reportable protocol violations include, but are not limited to:
- Randomization of an ineligible patient.
- Investigational Product (IP) Daily dose delivered is < 80% prescribed over a 3 day average.
  **Example:**
  Prescribed dose: 35g/day (80% = 28g)
  Dose received: Day 6: 30g
  Day 7: 20g
  Day 8: 30g
  3 Day Average Total: 80g/3 days = 26.67g/day average (<28g)

A protocol violation should be reported on Day 7:
• dose received is less than 80% (28g) prescribed AND
• 3 day average is less than 80% (28g) prescribed

Do not report Day 6 or Day 8 in the example above:
• Dose received on those study days is NOT less than 80%

When to report
Protocol violations are to be reported from randomization until end of the study duration (10 days post last successful grafting or ACU discharge or 3 months from ACU admission, whichever comes first).

Do NOT report dose related Protocol Violations (<80% over a 3 day average) on the following days:
1) Day of randomization
2) Day of discharge or end of study treatment (7 days post last successful grafting)
3) Day of death

Are you reporting a Protocol Violation today?
Indicate if a protocol violation occurred today by selecting ‘Yes’.

Date Violation Occurred
Enter the protocol violation into REDCap™ based on the date the violation occurred.

Date Violation Discovered
Enter the date when the violation was identified by site research staff.

Is the local site investigator aware of the violation?
Indicate whether the local qualified investigator has been made aware of this violation, Yes or No.

Type of violation
Using the options provided, check the box for the type of violation:
• Dose delivered is <80% prescribed over a 3 day average
• Dispensing/dosing error (an incorrect dose/product was given to patient)
• Accidental unblinding (the integrity of the study blind has been compromised)
• Enrollment of a patient that does not fulfill inclusion/exclusion criteria
• Unapproved procedures performed (failure to obtain consent)
• Other, please specify (briefly describe the type of protocol violation)

Reason for the Violation
Check the appropriate box and briefly describe the reason for the violation on the lines provided.
Describe the circumstances surrounding these violations. Check all that apply
• High gastric residual volumes
• Bowel perforation/obstruction
• Held for procedure/OR
• Other, specify details or attach Note to File:_________________

Are there supporting files to be emailed (preferred) or faxed?
Indicate if other supporting files are being sent.

Action taken by Research Coordinator/Responsible Delegate
Describe the action taken by the Research Coordinator/responsible delegate to prevent violation/problem from recurring.

Another Protocol Violation to add?  
Indicate if more than one protocol violation occurred on the same day, Yes or No. Report all Protocol Violations that occurred on that day by selecting ‘Yes’ and entering the PV data.

**Hospital Overview**  
Record data related to grafting status, acute care unit and hospital discharge, and mortality in REDCap™.

**ACU Discharge**  
Did the patient die in ACU?  
If the patient died in ACU, place a check in the ‘Yes’ box and record the date and time of death.

*Note: Record the death date and time documented on the death certificate. If this information is not available, record the date and time from the physician note. If the latter is not provided, record the date and time documented in the nurses charting.*

If the patient was discharged from ACU, place a check in the ‘No, patient discharged’ box and enter the date and time the patient was actually discharged from the ACU. Proceed to the Hospital discharge row.

If the patient is still in the ACU at 3 months from ACU admission, place a check in the ‘No, patient still in ACU at 3 months’ box. Proceed to Month 6 Follow-Up Assessments form.

**Hospital Discharge**  
Did the patient die in Hospital?  
If the patient died prior to hospital discharge, select ‘Yes’ and record the date and time of death.

If the patient was discharged from the hospital, select ‘No, patient discharged’ and enter the date and time the patient was actually discharged from the hospital. Proceed to ‘Discharged to’ row.

If the patient is still in the hospital at 3 months from ACU admission, select ‘No, patient still in hospital at 3 months’. Proceed to Month 6 Follow-Up Assessments form.

**Discharged to**  
If patient was discharged, select the location the patient was discharged to from the list below:  
- Ward in another hospital  
- ACU in another hospital  
- Long term care facility  
- Rehabilitation unit  
- Home  
- Other (Please Specify):

**Cause of Death**  
If patient died, document the cause of death from a post mortem report. If a post mortem report is not available, record the cause of death from the death certificate.
Month 6 Follow-up Assessments

Survival
The primary outcome of this trial is 6-month mortality. Every resource must be used to determine the status of each patient at 6 months (+/- 14 days) after admission to the ACU. The site must establish a system that ensures the ability to connect with the patient, SDM, family, or friend 6 months after ACU admission.

Was the survival status obtained?
Indicate if survival status was obtained, Yes or No.
NOTE: In order to select ‘No’ you must complete and document all contact attempts as outlined in the Survival Status NOT Obtained section below.

Survival Status Obtained Date
Record the date of the contact or information retrieval.

Source of information
In the following section we use the word ‘alternate contact person’ to refer to anyone, other than the patient, who is able to provide the requested information. This may be a family member, friend, neighbor, or caregiver to name a few. This does not need to be a legal representative (SDM) of the patient.

Record the source of the survival status information.
- Patient
- Alternate Contact Person (record the relationship between the alternate contact person and the patient)
- Family Physician
- Medical Records
- Obituaries
- Internet
- Other (Please specify)

Survival Status
Indicate if the patient is Alive or Deceased.

Date of death known?
Indicate if date of death is known, yes or No.
-If deceased and the date of death is known, record the date of death.
-If deceased and the date of death is unknown, record the last date the patient was known to be alive

Survival Status NOT Obtained
Confirm which of the following were completed
Confirm that all the listed avenues to access the patient survival status were completed. Record all attempts* to contact the patient and/or on the ‘Month 6 Follow-up Assessments: Contact Log’
- 3 attempts to contact the patient were made (mandatory)
- 3 attempts to contact the alternate contact person(s) were made (mandatory if applicable)
- Family doctor contacted (mandatory if available)
- No medical records on the patient available at month 6 (mandatory)
- Internet searches for the patient name did not reveal survival status (mandatory)

Last date known to be alive
Record the last date the patient was known to be alive.

Month 6 Follow-up Assessments: Contact Log
Record all contacts of, and attempts to contact, the patient and alternate contact person(s) for the Month 6 follow-up assessments on this log. There must be at least 3 attempts made to contact the patient and, if unsuccessful, 3 attempts made to contact the alternate contact person(s) to conduct the follow-up assessments.

An ‘attempt’ is defined as exhausting all available contacts for the patient and alternate contact person(s) (if available) at a given time point. Calls to the patient’s home, cell, and work numbers without reaching the patient do not constitute 3 attempts. These are all part of a single attempt to contact the patient as part of the first attempt outlined in the example below:

For example, the first attempt may include all of the following:
- Trying to call the patients
  - Cellular number
  - Home number
  - Work number
  - Other numbers/contacts
- If the patient cannot be reached then try to contact the alternate contact person(s) by calling their:
  - Cellular number
  - Home number
  - Work number
  - Other numbers/contacts

If both the patient and the alternate contact person(s) cannot be reached, conduct another ‘attempt’ at a different time of day and/or on a different day.

The primary goals of the month 6 assessments are to ascertain survival status and to obtain results from the patient to complete the questionnaires. If the patient is alive but unable to complete the questionnaires, then an ‘alternate contact person(s)’ such as a family member can complete the questionnaire for the patient.

Duration and Timing of Month 6 Follow-up Data Collection
Month 6 Follow-up Assessments are completed once. The SF-36, ADL, IADL and employment status assessments are to be conducted 6 months (± 14 days) after ACU admission.

NOTE: Late data is preferred to missing data. If you are not able to reach the patient or alternate contact person within the expected assessment period (± 14 days from 6 months after admission to your ACU), please continue to attempt to contact the patient to perform the assessments.

Was the patient/alternate contact person(s) contacted in advance to book an appointment for the month 6 follow-up visit?
Contact the patient/alternate contact person(s) 2 weeks prior to book a time for the month 6 follow-up assessment and record the date of contact on the log. Completion of all 4 questionnaires is estimated to take 45 minutes. Each questionnaire may be completed on different days or at different times if need be. It is strongly recommended to schedule time in advance with the patient/alternate contact person(s) to ensure her/his availability.

Date of attempt to contact patient/alternate contact person(s)
Record the date and time of contact. If you cannot reach the patient/alternate contact person(s) try a different time at each attempt.

If the patient was deceased as per the medical records or obituaries before contacts were made, record the date and time the survival status information was retrieved.

Patient Contact Method (Select all that apply)
Record all methods used to contact the patient.
- In person with patient
- Called patient (cell)
- Called patient (work)
- Called patient (home)
- Other contact (please specify)
If the patient was deceased as per the medical records or obituaries before any contact attempts were made, select ‘Other’ and record that the patient was deceased and record your source.

Is there a alternate contact person(s) available?
Record if information for alternate contact person(s) are available. If the patient completed all the assessments or was deceased before any contact attempts were made, select ‘Not required’.

Alternate contact person(s) Contact Method (Select all that apply)
If information is available, record all methods used to contact the alternate person.
- In person with alternate contact person(s)
- Called alternate contact person(s) (cell)
- Called alternate contact person(s) (work)
- Called alternate contact person(s) (home)
- Other contact (please specify)

Alternate Contact Person(s) Relationship with the Patient
Record the relationship between the alternate and the patient.
- Spouse/Partner
- Parent
- Child
- Friend.
- Other relationship (please specify)

Follow-up Assessments Completed
Indicate which of the following assessments were completed during this attempt, Yes, or No. Record whether the patient or the alternate contact person(s) completed the assessment. This may be different from form to form.
Note: It is always preferred to complete questionnaires with the patient when possible.

• Was the SF-36 completed?
• Was the Katz ADL completed?
• Was the Lawton IADL completed?
• Was the Employment Status questionnaire completed?

Was there a second contact attempt?
If all the follow-up assessments were not completed in the first attempt, indicate if there was a second attempt. If yes, record the information above.

Was there a third contact attempt?
If all the follow-up assessments were not completed in the first or second attempt, indicate if there was a third attempt. If yes, record the information above.

Reason Follow-up NOT completed
What was the reason all the follow-up assessment could not be completed?
If the follow-up assessments can not be completed, record the reason why.
• Deceased (Record date on the survival assessment)
• Patient refused
• Alternate contact person(s) refused (only if patient did not re-consent)
• Other (Please specify)

If the patient is deceased, record the date of death or date last known to be alive on the ‘Month 6 Survival Assessments’.

Refused is defined as the patient/alternate contact person(s) is unwilling to complete the follow-up questionnaires. This does not include reasons such as ‘not a good time’ or ‘I am not feeling well today’ etc. In those cases, set up a new date and time to call the patient/alternate contact person(s).

Health Related Quality of Life questionnaires
6 months (+/- 14 days) after admission to the acute care unit, the patient or family member/friend of the patient will be contacted via telephone and the following questionnaires administered. All associated data will be recorded in REDCap™.

• SF-36 Health related Quality of Life questionnaire (Appendix N)
• Activities of Daily Living-Katz Index (Appendix O)
• Instrumental Activities of Daily Living-Lawton Index (Appendix P)
• Employment Status (Appendix Q)

SF-36
The SF-36 Quality of Life survey is to be completed at 6 months (+/- 14 days) after ACU admission. Read the explanation at the top of the survey to the patient. Ensure the patient understands the responses should reflect her/his views about her/his own health. Remember not to interpret the questions for the patient. Each question means what he/she thinks it means, there is no right or wrong answer. Read each question to the patient followed by the response options. Record the patient’s response on the questionnaire worksheet. Maintain the completed worksheet with the patient study files, this is your source document for the completed questionnaire. Record the data in REDCap™.
Every attempt should be made to obtain this information from the patient directly however, if the patient is not available, able, or willing to answer the questions, the assessment may be completed by an alternate contact person.

**Katz ADL Index**
The Katz Index of Independence in Activities of Daily Living is to be completed at 6 months (+/- 14 days) after ACU admission to assess the level of patient independence related to self-care. The patient’s responses should reflect what he/she is actually able to do, not what they think they might be able to do under ideal circumstances. Read the definitions of ‘Independence’ and ‘Dependence’ to the patient as stated on the top of the Katz ADL form. Read each of the 6 activities to the patient followed by the independent and dependent descriptions. Allow the patient to make her/his own determination. Based on the patient’s response, record either 1 or 0 in the space provided for each activity. Maintain the completed worksheet with the patient study files, this is your source document for the completed questionnaire. Record the data in REDCap™.

Every attempt should be made to obtain this information from the patient directly however, if the patient is not available, able, or willing to answer the questions, the assessment may be completed by an alternate contact person.

**Lawton IADL Index**
The Lawton Instrumental Activities of Daily Living is to be completed at 6 months (+/- 14 days) after ACU admission to assess the level of patient functional ability related to domestic and community activities. The patient’s responses should reflect her/his highest functional level, not the activities they actual do. For example, if a patient is not the person in the household that does the laundry, but the patient is capable of doing her/his own laundry independently select ‘Does personal laundry completely’. Read each of the 8 activities to the patient followed by the response options. Remind the patient to indicate her/his highest functional ability. Allow the patient to make her/his own determination. Based on the patient’s response for each activity, circle the corresponding number on the form. Maintain the completed worksheet with the patient study files, this is your source document for the completed questionnaire. Record the data in REDCap™.

Every attempt should be made to obtain this information from the patient directly however, if the patient is not available, able, or willing to answer the questions, the assessment may be completed by an alternate contact person.

**Employment Status**
The Employment Status questionnaire is to be completed at 6 months (+/- 14 days) after ACU admission to assess the effect of the burn injury on the patient’s employment status. Read each question to the patient and record her/his response. Where applicable, read the response options to the patient. Allow the patient to make her/his own determination. Read each question sequentially. Follow the instructions on the form regarding skipping questions associated with responses to questions 1, 5, and 6. Indicate the patient’s response to each question by marking the corresponding box. Maintain the completed worksheet with the patient study files, this is your source document for the completed questionnaire. Record the data in REDCap™.
Every attempt should be made to obtain this information from the patient directly however, if the patient is not available, able, or willing to answer the questions, the assessment may be completed by an alternate contact person.

**It is encouraged to schedule reminders in your calendar for the month 6 follow up interviews.**

If you are unable to complete all questionnaires during a single telephone call, make every effort to complete the questionnaire you are working on. Ask if you may call them back to finish the remaining questionnaires. The following day is ideal, however anytime during the assessment window is acceptable. Schedule a time that is convenient for the patient.

If they do not wish to finish the remaining questionnaires, even at a later date, complete the Month 6 Follow-up Assessments: Contact Log as per instructions above.

**Adverse Events**

Adverse events are any untoward medical occurrences in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Given the high acuity of diseases and morbidity related to burns, adverse events are NOT to be reported to CERU, only SAEs.

**Serious Adverse Events**

SAE forms must be completed in REDCAP™ in real time. REDCAP™ may be accessed via [http://www.criticalcarenutrition.com](http://www.criticalcarenutrition.com) or directly at: [https://ceru.hpcvl.queensu.ca/EDC/redcap/](https://ceru.hpcvl.queensu.ca/EDC/redcap/)

The SAE forms are listed at the bottom of the Event Grid, example below:

A **Serious Adverse Event (SAE)** is defined as any untoward medical occurrence that at any dose:

- Results in death.
- Is life-threatening (refers to an event in which the study participant was, in the opinion of the qualified investigator (QI), at risk of death from the event if medical intervention had not occurred. NOTE: This does not include an event that hypothetically had it occurred in a more serious form, might have caused death).
- Requires in patient hospitalization or prolongation of existing hospitalization.
- Results in persistent or significant disability/incapacity (i.e. a substantial disruption in an individual’s ability to conduct normal life functions).
- Is a congenital anomaly or birth defect.
Other medically important condition (Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious events when, based on medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed above).

**Reporting Period**
Subjects should be monitored for SAEs from randomization until 10 days post last successful graft, or discharge from the acute care unit, or 3 months after admission to the acute care unit, whichever comes first. All SAEs should be documented and reported to the central study team via REDCap™ within 24h of becoming aware of the event. Any follow-up information should be sent as soon as it becomes available.

**Regulatory Reporting**
The central study team will be responsible for reporting any events that meet the criteria for expedited reporting. Cooperation from the site is required to ensure any regulatory timelines are adhered to in the reporting of SAE reports.

As with any study there may be other risks or side effects that we do not know about with administration of these study supplements. The Site Investigator must adhere closely to the ICH-GCP Guidelines, however when in doubt he/she can contact the Project Leader for the study.

**Patient Confidentiality**
By definition, and in the context of a clinical trial, confidentiality refers to prevention of disclosure, to other than authorized individuals, of a Patient’s identity and of records that could identify a Patient. Care and diligence in protecting confidential Patient information must be exercised throughout the duration of the RE-ENERGIZE Study.

With this in mind, prior to forwarding any documentation (i.e. as attachments to a Serious Adverse Event [SAE] report) to CERU, all patient identifiers other than the Patient’s Initials should be masked.

**Reportable SAEs**
All Serious Adverse Events that are unexpected or related must be reported to CERU within 24 hrs of becoming aware of the event by filling out the Serious Adverse Events Initial Report in REDCap™. (see Appendix R for worksheet ).

- **Unexpected SAE:** An event that is serious (see definition above) and is not expected due to the progression of the underlying disease or co-morbid illnesses.

  Examples of serious and unexpected SAEs and hence MUST be reported to CERU within 24 hrs of becoming aware of the event:
  - Cardiac arrest in a patient without a history of cardiac disease.
  - New seizure in the absence of a previous seizure disorder.
  - Worsening encephalopathy in the absence of liver disease.

- **Related SAE:** An event that is serious (see definition above) and is considered by the site investigator to be possibly or probably related to the study intervention. Refer to the definitions of relatedness provided in the following section under the heading ‘Relationship of SAE to study supplements’.
Death (outcome)
Do not record death as an SAE.
If a reportable SAE results in death, record death as the outcome. Record the condition that lead to death as the SAE, for example: sepsis

Respiratory Failure
Do not record respiratory failure as an SAE.
Record the condition that caused respiratory failure as the SAE, for example: sepsis.

Initial SAE Report
This form must be completed by the Research Coordinator in consultation with Site Investigator or sub-I and requires the signature of the Site Investigator/sub-I.

All known data elements on the form must be completed within 24 hrs of discovery of the event. It may be that certain aspects of the form may change (for example, the date of resolution may not be known at the time of reporting). This may be clarified in the narrative on the Final report.

The following fields of the Initial form must be completed:
- Patient identification
  - Your RE-ENERGIZE ® site number
  - RE-ENERGIZE ® enrollment number
  - Age
  - Sex, select male or female
  - Height
  - Weight
- Name of Site Investigator
- Name of person reporting the SAE
- SAE #: Record the sequential SAE # for the patient; i.e. for the first SAE for the patient, enter 01. For the second SAE for the patient, enter 02.
- Serious Adverse Event Reported (only one per form):
  Record the event that you are reporting (must be serious and unexpected).
- Date SAE reported
- Date became aware of SAE
- Seriousness of the SAE: (select all that apply):
  - patient died (if so, record this date in the Outcomes section)
  - life threatening
  - requires or prolongs hospitalization
  - results in persistent or significant disability/incapacity
  - may require medical or surgical intervention to prevent one of the other outcomes.
  - congenital anomaly/birth defect
  - other serious medical event
- Outcomes: Select the most appropriate at the time of the initial report:
  - complete recovery/return to baseline (include date of recovery)
  - alive with sequelae
  - death (include date of death)
  - SAE persisting
  - unknown/lost to follow up
- Record the date (dd/mmm/yyyy format) and time (hh:mm) for the following:
- Onset of SAE
- ICU admission
- Start of study supplement
- Stop of study supplement (if available at the time of this report)

- **Action taken:** Select all that apply from the following
  - none
  - uncertain
  - procedure or physical therapy
  - blood or blood products
  - prescription drug therapy
  - non-prescription drug therapy
  - hospitalization
  - IV fluids
  - Other

- **Action taken with Study Supplements:** Select only one of the following:
  - none (including not on study supplements)
  - dose reduced, interrupted or therapy delayed (include date/time)
  - study supplements stopped permanently due to SAE (include date/time).

- **Relationship of SAE to the study supplements:** The determination of the relationship of the event to the supplements is to be made by the Site Investigator/sub-I and recorded by the Research Coordinator. To assist the Investigator in making this assessment, the following definitions have been provided (select only one):

  - **Not related:** A serious adverse event that is clearly due to extraneous causes (disease, environment, etc.) and does not meet the criteria for drug relationship listed under ‘Possibly’ or ‘Probably’.
  - **Unlikely related:** A serious adverse event that is more likely due to other causes than the study supplements
  - **Possibly related:** Suggests that the association of this SAE with the study supplements is unknown and the event is not reasonably supported by other conditions.
  - **Probably related:** Suggests that a reasonable temporal sequence of this SAE with study supplement administration exists and the association of the event with the study supplement seems likely.

Upon completing the form, select ‘Save and Stay’.
After saving the form, select the ‘PDF with saved data’ button on the top right of the form, see example below, and save the form to your desktop.

Print and file the completed SAE form in the patient study folder. Scan and email any accompanying documents, such as labs, x-rays, CT scans to the Project Leader at: danserem@kgh.kari.net. Remember to de-identify any patient records before sending them.

For SAE Initial Report Worksheet, see Appendix R.

**Follow-up/Final SAE Report**
For every SAE that was reported, a Serious Adverse Events Follow-up/Final Report must be completed in REDCAP™

In the event that the event has not resolved, been explained or stabilized, the Project Leader will collaborate with the Research Coordinator for additional details and further follow-up reporting. This form **must be completed by the Site Investigator/designate** by reviewing the Serious Adverse Events Report (Initial) and the patient’s medical chart. To make this process easier, it is strongly recommended that this be done as close to the event as possible.

Since the information in the Follow-up/Final Report will be reviewed by the Data Monitoring Committee, it **must** include details on the patients admitting diagnosis, co-morbidities, a chronological complete narration of the events leading to the SAE, the nature of the SAE, action taken with the study supplements, the outcome and the relationship of the event to the study supplements.

The following additional documentation is required and is to be attached to the follow-up/final report:

- Medication the patient received in the 48 hours before the onset of the SAE
- Laboratory results related to the SAE must also be provided.
  - Examples: if the event is cardiac arrest, provide cardiac enzymes; if the event is cholestasis/pancreatitis, provide liver function tests & amylases. For further clarification about which lab tests are relevant, the Research Coordinator is encouraged to ask the Site Investigator.
All data fields in the Follow-up/Final form must be completed:

- **Patient identification**: Site #, enrollment # and SAE # can be copied from the initial reporting form.
- **Patient medical history**, co-morbid illness and reason for admission to hospital: provide a detailed narrative of this information.
- **Admitting diagnosis** to ACU and chronological events leading to the SAE: provide a detailed narrative of this information.
- **Chronological events proceeding the SAE until time of report**: provide a detailed narrative of this information and attach other reports/details as needed.
- **Concomitant Medications**: list all medications given within 48 hrs before the onset of the SAE.
- **Laboratory Results and Investigations**: record all lab results and investigations done that are pertinent to the SAE. For example, cardiac enzymes, ECG results in the event of a cardiac arrest.
- **Confirmation of Unexpected nature of the SAE**: record the pertinent clinical features that, in the opinion of the Site Investigator, made him/her think that the event was unexpected vs. due to the progression of underlying disease.
- **Relationship of SAE to the Study supplements**: The determination of the relationship of the event to the supplements is to be done by the Site Investigator/delegate in collaboration with the Research Coordinator. To assist the Investigator in making this assessment see earlier in this section for definitions.
- **Rationale for relationship of the SAE to the study supplements vs. progression of underlying disease**: If the event is considered to be related to the study supplement, record the pertinent clinical features that, in the opinion of the Site Investigator, made him/her think that the event was related to the study supplements vs. the progression of underlying disease. Refer to the definitions of degree of relationship to the study supplements (not related, unlikely related, possibly related, probably related).
- **Outcomes**: Select the most appropriate at the time of the FOLLOW-UP report
  - complete recovery/return to baseline (include date of recovery)
  - alive with sequelae
  - death (include date of death)
  - SAE persisting
  - unknown/lost to followup
- **Action taken**: Select all actions taken from the onset of SAE, including those that occurred between the initial report and the follow-up report:
  - none
  - uncertain
  - procedure or physical therapy
  - blood or blood products
  - prescription drug therapy
  - non-prescription drug therapy
  - hospitalization
  - IV fluids
  - Other
- **Action taken with Study Supplements**:
  - none (including not on study supplements)
  - dose reduced, interrupted or therapy delayed (include date/time)
  - study supplements stopped permanently due to SAE (include date/time).
• **Event reported to IRB (Institutional Review Board) / REB (Research Ethics Board):** indicate whether this event was reported to your IRB/REB.

• **Further Details:** add any further details concerning the SAE.

The completed-Follow-up/Final Report must be signed by the Site Investigator and filed in the patient study folder. Scan and email relevant medication and lab documentation to the Project Leader at: danserem@kgh.kari.net.

IMPORTANT: Remember to de-identify any patient records before sending them to the Project Leader.

For SAE Follow-up/Final Report worksheet, see Appendix S.

Any patient who experiences a serious adverse event during the study period, should be followed by the Research Coordinator until:

- the event resolves
- an outcome is reached, or
- the event is otherwise explained or stabilized

If follow-up information reveals that the event no longer meets the serious, unexpected, or drug related criteria, this information will be provided to Health Canada, the Medical Monitor, the Data Monitoring Committee, Steering Committee & the manufacturer of the investigational products.
Appendices
A. Delegation of Authority Log
B. Lund and Browder chart
C. NutreStore™ (L-Glutamine) monograph
D. Maltrin M-100 maltodextrin monograph
E. Nursing Procedures
F. Dosing Weight Chart
G. Enteral Feeding Protocol
H. Contact Information sheet
I. Medical/Physician Orders
J. Comorbidities list
K. EN Formula List
L. Protein Supplement List
M. Gram Negative Bacteria List (sub-List of Gram Positive bacteria)
N. SF-36 Health related Quality of Life questionnaire
O. Activities of Daily Living (Katz Index)
P. Instrumental Activities of Daily Living (Lawton Index)
Q. Employment Status
R. SAE Initial Report worksheet
S. SAE Follow-up/Final Report worksheet